https://trial.medpath.com/news/23d652a681e6243a/phase-3-clear-trial-evaluating-organ-specific-progression-patterns 2025-01-10T14:00:54+00:00 hourly 0.9 https://trial.medpath.com/news/e6fab7dbfad05b70/verismo-therapeutics-announces-first-patient-infused-in-phase-1-celestial-301-clinical-trial-of-synkir-310 2025-01-10T13:59:04+00:00 hourly 0.9 https://trial.medpath.com/news/cfdc21f04bb36758/johnson-johnson-medtech-announces-ce-mark-approval-for-dual-energy-thermocool-smarttouchtm-sf-catheter 2025-01-10T13:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/2050ae86a74dfc5b/alyea-therapeutics-to-present-at-biotech-showcase-2025 2025-01-10T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/565577675fae1f91/restem-announces-key-business-objectives-for-2025-and-corporate-update 2025-01-10T13:28:27+00:00 hourly 0.9 https://trial.medpath.com/news/90d258f23efe8833/newamsterdam-pharma-highlights-2024-achievements-and-outlines-2025-strategic-priorities 2025-01-10T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/e1177f3adfb20c15/barinthus-bio-shifts-focus-to-immunology-and-inflammation-announces-financial-restructuring 2025-01-10T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/068ceec1103206a2/4dmt-announces-positive-interim-data-from-4d-150-spectra-clinical-trial-in-dme-and-alignment-with-fda-on-registrational-path 2025-01-10T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/404f1e8959a9ab5f/fda-updates-and-pharma-developments-j-j-pfizer-gsk-and-novo-nordisk 2025-01-10T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/23348e11989bb112/acumen-announces-phase-1-intercept-ad-study-publication 2025-01-10T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/a2c0998799fa644e/intensity-therapeutics-advances-in-breast-cancer-treatment-with-int230-6 2025-01-10T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/713add3a32548af9/rhythm-pharmaceuticals-reports-preliminary-2024-financials-and-clinical-trial-progress 2025-01-10T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/62fd2fc1173618e6/fda-grants-510-k-clearance-to-ventris-medical-s-backpack-for-orthopaedic-use 2025-01-10T12:50:57+00:00 hourly 0.9 https://trial.medpath.com/news/95494434c1e6ac71/study-links-higher-psoriasis-acceptance-to-improved-clinical-outcomes-and-quality-of-life 2025-01-10T12:47:12+00:00 hourly 0.9 https://trial.medpath.com/news/06fc50c47ae1ed77/crinetics-announces-positive-topline-results-from-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia-cah 2025-01-10T12:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/26ef351fc3a9eecc/passage-bio-announces-data-from-uplift-d-study-in-ftd-grn 2025-01-10T12:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/fce359ade9b3c31c/real-world-data-confirms-ibrutinib-s-safety-and-efficacy-in-japanese-cll-sll-patients 2025-01-10T12:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ed8ae1376938cf6/y-mabs-announces-strategic-business-update-and-2025-priorities 2025-01-10T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/55b47a29d91996a2/vertigo-global-clinical-trials-review-2024-now-available 2025-01-10T12:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d6f47c05cb36e21/alentis-therapeutics-reports-positive-results-from-organ-fibrosis-treatment-trials 2025-01-10T12:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/b0b0f1ac6010ec4d/nektar-therapeutics-completes-enrollment-in-phase-2b-study-for-atopic-dermatitis-treatment 2025-01-10T12:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/920c1c1ac192fefe/monte-rosa-therapeutics-announces-2025-milestones-and-corporate-update 2025-01-10T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/93b79782dafb2c96/neumirna-raises-eur20m-for-clinical-trials-of-epilepsy-drug 2025-01-10T12:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/0ecba206c1dd3d8e/gh-research-announces-primary-endpoint-met-in-two-phase-2a-trials 2025-01-10T12:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/cbed023ff2ab4fe5/arvinas-plans-two-phase-3-trials-for-breakthrough-breast-cancer-treatment 2025-01-10T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1fcae57e0d88408c/zymeworks-in-focus-for-insider-activity-catalysts-ahead 2025-01-10T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b90d42b3e6809f6c/dyne-therapeutics-reports-promising-clinical-data-for-dm1-and-dmd-treatments 2025-01-10T11:41:28+00:00 hourly 0.9 https://trial.medpath.com/news/ff5fd01fed09d562/ouro-medicines-launches-with-120m-to-develop-t-cell-engagers-for-autoimmune-diseases 2025-01-10T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4d18f8ed2e908c8/fda-grants-fast-track-status-to-mersana-s-breast-cancer-drug-emi-le-for-expanded-use 2025-01-10T11:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/57f9936e86d0bb1e/orexo-announces-positive-data-from-clinical-study-of-ox640-evaluating-allergic-reactions 2025-01-10T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/d878a3f50cbc53ec/fda-grants-fast-track-status-to-mersana-s-breast-cancer-drug-for-expanded-use 2025-01-10T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/823ba05271bf21e9/mersana-therapeutics-announces-positive-initial-clinical-data-from-phase-1-trial-of-emiltatug-ledadotin 2025-01-10T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a3c29d6e74fbd362/fda-s-new-ldt-regulations-face-industry-pushback-and-legislative-uncertainty 2025-01-10T09:43:44+00:00 hourly 0.9 https://trial.medpath.com/news/9aeb686b5f4c9be5/io-biotech-completes-phase-2-enrollment-ahead-of-schedule-for-io102-io103-cancer-vaccine-trial 2025-01-10T08:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f86c82e5914bab2/comparative-study-of-whole-genome-transcriptome-sequencing-vs-panel-sequencing-in-cancer-treatment 2025-01-10T08:29:16+00:00 hourly 0.9 https://trial.medpath.com/news/c9baae578a54f87c/lava-therapeutics-initiates-phase-1-trial-for-novel-cancer-treatment-lava-1266 2025-01-10T08:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/1333b8f9a1de428e/fda-accepts-review-of-gsk-plc-s-prefilled-shingrix-syringe-for-vaccine-approval 2025-01-10T08:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/1d96b7c90158fab6/teva-and-samsung-bioepis-launch-epysqli-a-30-discounted-biosimilar-to-soliris-for-rare-diseases 2025-01-10T08:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/a8ed29c09f53a948/tyra-biosciences-receives-fda-ind-clearance-for-phase-2-study-of-tyra-300-in-non-muscle-invasive-bladder-cancer 2025-01-10T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/735f0ee8033251dc/cargo-therapeutics-announces-2025-milestones-and-corporate-update 2025-01-10T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/334ed029446b0689/health-literacy-crisis-88-of-adults-struggle-with-medical-information-understanding 2025-01-10T07:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/f7d19316f2ced3cd/sn-bioscience-advances-snb-101-to-phase-2-clinical-trials-with-fda-ind-clearance 2025-01-10T07:45:33+00:00 hourly 0.9 https://trial.medpath.com/news/2b999ad58dd4c041/bayer-s-investigational-mri-contrast-agent-gadoquatrane-meets-primary-and-main-secondary-endpoints-in-phase-iii-studies 2025-01-10T07:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/821f9290cc76b838/global-clinical-trials-for-herpes-zoster-shingles-in-2024-a-comprehensive-review 2025-01-10T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/1d3681619753ffda/atai-life-sciences-strengthens-leadership-team-to-advance-psychedelic-therapeutics-for-mental-health 2025-01-10T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5353b8ff6c32e20/fda-s-new-and-supplemental-approvals-in-december 2025-01-10T06:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/59cf513ee763ff95/ai-breakthrough-in-cancer-detection-and-treatment-major-advances-in-breast-cancer-screening-and-immunotherapy-prediction 2025-01-10T06:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/96b42c82c51c4fce/izotropic-files-pre-submission-with-u-s-fda-for-breast-cancer-screening 2025-01-10T06:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/56fd79848b851ffe/novel-respiratory-and-emg-patterns-identified-as-reliable-indicators-of-dysphagia-in-myasthenia-gravis 2025-01-10T06:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/9fbaa2203e362113/precision-biosciences-arcus-platform-shows-promising-clinical-outcomes-in-gene-editing-trial 2025-01-10T05:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/c1099814e2b2a2ce/neumora-s-depression-drug-navacaprant-fails-phase-iii-trial-shares-plummet 2025-01-10T04:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/595beba6b2b07d9d/spinal-cord-injury-treatment-market-to-see-significant-growth-by-2034 2025-01-10T02:45:42+00:00 hourly 0.9 https://trial.medpath.com/news/83e66768223f5bd9/fda-drug-review-chief-patrizia-cavazzoni-announces-departure-amid-leadership-transitions 2025-01-10T02:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/51ab96496eb56926/early-stage-alzheimer-s-new-guidelines-reveal-10-year-window-for-intervention-before-symptoms 2025-01-10T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0e8266ba9e3a3c9c/new-drug-hope-for-prostate-cancer-patients 2025-01-10T00:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/7944783b7e1d76fc/efficacy-and-safety-of-liwei-capsule-in-chronic-non-atrophic-gastritis-with-erosions 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/88cbda066e3a1243/ema-initiates-review-of-rocket-pharma-s-gene-therapy-for-fanconi-anaemia 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/de9f46f060fe3e38/compass-pathways-announces-pricing-of-underwritten-offering 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9619cae2ff82842/obesity-biotech-metsera-files-for-a-100-million-ipo 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9fea40aa4b9ffa49/insights-into-clinical-trials-and-research-practices 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe7fc7c95cbf9834/world-s-largest-proteomics-trial-launched-by-uk-biobank 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3645161bd6eae966/4dmt-prioritizes-4d-150-for-wet-amd-and-dme-and-4d-710-for-cystic-fibrosis-in-strategic-pipeline-focus 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f98a5f523d8007a/japanese-dengue-vaccine-tak-003-approved-for-use-in-argentina 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/71719ebe5337ef4f/latest-updates-on-fda-approvals-and-processes 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/232d25a63e0bd0a0/lokon-pharma-advances-in-cancer-treatment-with-load-family-clinical-trials 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/260931c0c1b9c874/fda-accelerates-review-for-bayer-s-parkinson-s-stem-cell-therapy 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/267da354227b30e2/annexon-inc-advances-in-neuroinflammatory-disease-treatments 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a1fe49ad330ba108/global-diabetic-retinopathy-clinical-trials-landscape-analysis-reveals-key-research-trends-for-2024 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/231e0f9c748163b4/ai-driven-discovery-unveils-cancer-therapy-breakthrough 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/43cbd3fa94d6d159/self-destruct-tb-vaccine-shows-promise-in-boosting-safety-efficacy 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1bb8803ffa80716a/cepheus-study-validates-mrd-as-critical-biomarker-in-multiple-myeloma-treatment 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/926ad79eda403522/inz-701-shows-promising-survival-benefits-in-infants-with-enpp1-deficiency-trial-enrollment-complete 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b95f7a2b869c36a3/abbvie-announces-3-5b-impairment-charge-due-to-failed-schizophrenia-drug 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c90b92b04306b337/belatacept-use-and-risk-of-post-transplant-lymphoproliferative-disorder-in-kidney-transplant-recipients 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5a3da574ae648390/study-shows-improvement-in-family-centered-care-practices-in-nicus-following-educational-intervention 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd04a961949d6e16/pharmaceutical-industry-updates-trials-stocks-and-acquisitions 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b0e99c982191694f/study-questions-efficacy-of-spinal-fusion-over-decompression-alone-for-degenerative-spondylolisthesis 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b4f586baa4708b80/fda-approves-seattle-genetics-advanced-breast-cancer-drug-tukysa 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ccd88febfc8f7952/bioxytran-s-preprint-highlights-galectin-3-modulation-as-key-to-enhancing-immunotherapy-efficacy 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1543e6b7d45b44d3/cascada-silver-launches-phase-ii-drilling-at-angie-project 2025-01-09T22:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/cf293b76089cecdb/chordia-therapeutics-secures-orphan-drug-designation-for-rogocekib-in-the-u-s 2025-01-09T22:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/046f738578565e92/first-patient-with-multiple-myeloma-dosed-in-esobiotec-s-trial-for-in-vivo-car-t-eso-t01 2025-01-09T22:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/a277b0290e4e3a26/fda-grants-bbo-8520-fast-track-designation-for-krasg12c-mutant-mnsclc 2025-01-09T21:50:47+00:00 hourly 0.9 https://trial.medpath.com/news/aad6ba5d0ffa7460/igm-biosciences-halts-development-of-top-drugs-and-announces-workforce-reduction 2025-01-09T21:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/e0f58ef1c3e1322d/igm-biosciences-downgraded-by-bmo-capital-following-strategic-update 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/7e844671c3b329da/aptose-announces-first-aml-patients-dosed-with-tuspetinib-triplet-frontline-therapy-in-tuscany-trial 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/8b1a49698b428d02/intellia-therapeutics-announces-strategic-reorganization-and-2025-milestones 2025-01-09T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6c6f96866b3eb55c/abivax-sa-advances-in-phase-3-trials-for-ulcerative-colitis-treatment 2025-01-09T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/5c305d6a33af12ff/cage-bio-announces-phase-2b-trial-for-cgb-500-in-atopic-dermatitis-treatment 2025-01-09T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/35fc5eb575c7fdf3/real-world-discontinuations-of-ocrelizumab-in-ms-comparable-to-pivotal-trials 2025-01-09T19:25:25+00:00 hourly 0.9 https://trial.medpath.com/news/7f99e6960860bea6/astra-merck-drugs-set-to-shake-up-liver-cancer-treatment 2025-01-09T18:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/980b7264e8a93f32/contineum-concludes-enrolment-in-phase-ii-multiple-sclerosis-therapy-trial 2025-01-09T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/455e44d762967baf/arovella-secures-20m-for-phase-1-clinical-trial-and-pipeline-expansion 2025-01-09T16:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/c2f69bb41788e190/new-car-t-clinical-trials-underway-at-roswell-park-for-solid-tumor-non-cancerous-diseases 2025-01-09T16:42:51+00:00 hourly 0.9 https://trial.medpath.com/news/8ad2a59468381059/new-phase-2a-findings-on-img-007-treatment-for-atopic-dermatitis-show-promising-results 2025-01-09T16:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/084a2daccd8171db/phase-ia-study-of-novel-anti-her2-antibody-drug-conjugate-gq1001-shows-promise-in-treating-her2-positive-advanced-solid-tumors 2025-01-09T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/a7b758af7e9bb97b/abivax-achieves-key-milestone-in-phase-3-abtect-trial-enrollment 2025-01-09T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/2e4c19462894feff/study-finds-care-after-donor-stem-cell-transplant-can-be-safely-shared-between-transplant-centers-and-local-oncologists 2025-01-09T16:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/f1fc0e030e5e5e29/vir-biotechnology-upgraded-to-overweight-by-morgan-stanley 2025-01-09T16:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/685b0c47cbfecfb1/innovative-approach-to-cancer-treatment-targeted-protein-degradation 2025-01-09T16:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/f709a114ac0d3ad4/thetis-pharmaceuticals-secures-9m-funding-to-advance-novel-oral-ibd-treatment 2025-01-09T16:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/9885562bfe1edbba/stroke-trial-tests-innovative-device-to-combat-arm-weakness 2025-01-09T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe0c9b02df4b04bb/durvalumab-plus-vaccine-therapy-shows-promise-in-bcg-unresponsive-nmibc 2025-01-09T16:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/8a9655bd307bac62/gildeuretinol-shows-promise-in-halting-stargardt-disease-progression 2025-01-09T16:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/a3c0c5fb779dfca2/non-histone-lactylation-emerges-as-key-regulator-in-cancer-progression-and-therapeutic-target 2025-01-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fef8e0b930c78edd/three-pronged-treatment-improves-prognosis-for-inoperable-liver-cancer 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc39788b255329c5/tenpoint-therapeutics-announces-positive-topline-data-from-brio-ii-phase-3-trial 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b2f6a4580d8433b/9mw2821-toripalimab-granted-breakthrough-therapy-designation-in-china-for-muc 2025-01-09T15:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/0c9508ea51879438/study-on-enhanced-oral-hygiene-program-for-cleft-patients 2025-01-09T15:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/22860f52b21533df/cristcot-s-phase-iii-ulcerative-colitis-suppository-trial-meets-endpoints 2025-01-09T15:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/4b0ac07222777020/argon-medical-announces-first-patient-enrollment-in-clean-pe-study-for-pulmonary-embolism-treatment 2025-01-09T15:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/21efacecfef63de9/clinical-trial-assessed-acupuncture-for-severe-combat-related-ptsd 2025-01-09T15:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/ac7bf769f320bd84/precision-biosciences-announces-complete-clinical-response-in-otc-hope-study-with-ecur-506 2025-01-09T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/5511a9c864b7e99e/effects-of-ultrasound-guided-recruitment-manoeuvres-on-postoperative-pulmonary-complications-in-obese-patients 2025-01-09T14:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/31a5646008dc376d/biofidelity-and-cellcarta-partner-to-deploy-aspyre-lung-in-global-clinical-trials 2025-01-09T14:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/9fabac0276f16f65/exelixis-cabometyx-cancer-drug-review-advances-as-fda-drops-advisory-meeting-requirement 2025-01-09T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/4f51e21dfc93b40c/real-world-data-supports-efficacy-of-opdivo-plus-yervoy-in-mrcc-treatment 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f460539a02fde8ee/limited-benefits-of-ctdna-testing-in-colorectal-cancer-surveillance-study-finds 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4d00e0aa794c760/abdera-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-09T13:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/8708be7837116ce7/first-u-s-h5n1-bird-flu-death-reported-in-louisiana-amid-low-overall-risk 2025-01-09T13:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/c211f94ed275506a/mineralys-therapeutics-advances-lorundrostat-to-phase-2-trials 2025-01-09T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/d697ae67e419fcd2/rigel-announces-r289-granted-orphan-drug-designation-by-the-fda-for-mds 2025-01-09T13:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/29bc4b183ac456a7/nivolumab-combined-with-cisplatin-and-radiotherapy-shows-improved-disease-free-survival-in-locally-advanced-scchn 2025-01-09T13:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/d24af472cb6e416d/j-j-s-nipocalimab-receives-fda-priority-review-for-generalized-myasthenia-gravis-treatment 2025-01-09T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/77f36eb50ca91bac/nimbus-therapeutics-advances-oncology-pipeline-with-ind-submission-for-ndi-219216 2025-01-09T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/db0d30492bb7463d/affinia-therapeutics-announces-development-candidate-for-bag3-dcm-and-completion-of-pre-ind-meeting-with-the-fda 2025-01-09T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb3841d815dcc986/rapport-therapeutics-announces-new-phase-1-data-supporting-rap-219-s-potential-for-cns-disorders 2025-01-09T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/3bf9344959545ca3/zentalis-cancer-drug-azenosertib-receives-fda-fast-track-status-for-ovarian-cancer-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/05b8cffe853e7172/puretech-s-cancer-drug-lyt-200-secures-fda-fast-track-status-for-leukemia-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/72ab28bef1ed88a9/peerbridge-health-launches-cor-insight-trial-for-ai-enabled-cardiac-and-cardiopulmonary-diagnostics 2025-01-09T12:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/77a41455360931ca/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate 2025-01-09T11:54:49+00:00 hourly 0.9 https://trial.medpath.com/news/090ed67b6150a912/european-pharmaceutical-industry-pushes-for-rapid-digital-package-insert-transition 2025-01-09T11:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/933cf49d2202eb07/genenta-enhances-partnership-with-agc-biologics-for-advanced-cell-therapy-manufacturing 2025-01-09T11:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/a4011c1151e914f1/maat-pharma-share-price-rises-on-positive-clinical-trial-results 2025-01-09T11:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/77efa4708bbe4f8c/aviceda-therapeutics-secures-207-5-million-series-c-financing-for-geographic-atrophy-treatment 2025-01-09T11:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/46b0c32f7fdd4717/lung-cancer-test-oracle-predicts-survival-better-than-current-methods 2025-01-09T10:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/7d573d17cca3d49b/jeito-capital-leads-67-5m-series-b-financing-for-cardiovascular-gene-therapy 2025-01-09T10:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/cb7d19862e94bde5/second-university-of-minnesota-study-shows-no-hydroxychloroquine-benefit-in-covid-19-fight 2025-01-09T10:45:22+00:00 hourly 0.9 https://trial.medpath.com/news/2be6614e0627f8ba/clinical-and-radiographic-evaluation-of-silver-diamine-fluoride-versus-mineral-trioxide-aggregate-in-indirect-pulp-capping 2025-01-09T10:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/08bd559682675cf4/regional-chemotherapy-for-colorectal-liver-metastases-a-retrospective-study 2025-01-09T10:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/c4f1a1068d497563/jimmy-carter-s-melanoma-treatment-journey-revolutionizes-immunotherapy-acceptance-in-cancer-care 2025-01-09T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d27a5fe61c1b2f8/alzheimer-s-disease-market-set-to-surge-to-19-3b-by-2033-driven-by-novel-therapies 2025-01-09T09:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/8c4fd73369888dfe/lyell-immunopharma-advances-next-generation-car-t-cell-therapy-impt-314-for-large-b-cell-lymphoma 2025-01-09T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6e2bb77881a1d478/maat-pharma-announces-positive-topline-results 2025-01-09T08:57:18+00:00 hourly 0.9 https://trial.medpath.com/news/ba91df3ec4c83aae/aardvark-therapeutics-strengthens-board-with-industry-leaders 2025-01-09T08:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/9eee50f49c7074bf/diabetes-prevention-program-shows-long-term-success-in-delaying-type-2-diabetes 2025-01-09T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/ed8d3c13ebd01f74/european-commission-approves-palforzia-r-for-toddlers-with-peanut-allergy 2025-01-09T08:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/1e8ba3385ca00065/biotest-submits-biologics-license-application-for-fibrinogen-to-the-fda 2025-01-09T08:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/50c53e3ffe9b4dcb/large-scale-study-links-vitiligo-to-elevated-cardiovascular-disease-risk 2025-01-09T08:00:06+00:00 hourly 0.9 https://trial.medpath.com/news/b29f51eec4e32eb5/elinzanetant-meets-all-primary-and-secondary-endpoints-in-phase-iii-study-oasis-4 2025-01-09T07:53:11+00:00 hourly 0.9 https://trial.medpath.com/news/d294dc7120b677cf/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-clinical-trial 2025-01-09T07:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/f751507b4ce0fdd1/azafaros-to-present-at-j-p-morgan-s-43rd-annual-healthcare-conference 2025-01-09T07:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/c50ef195f06b67f5/evaluation-of-one-step-nucleic-acid-amplification-for-detection-of-lymph-node-metastases-in-endometrial-cancer 2025-01-09T07:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/689685f31c85f00d/cosmo-pharmaceuticals-announces-record-revenue-and-strong-financial-position-for-2024 2025-01-09T07:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/3e69b09adda2a78f/study-reveals-unique-psoriasis-care-perspectives-among-latine-patients-in-urban-healthcare-setting 2025-01-09T07:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/fcdf6b0672eeaf93/schizophrenia-market-forecasted-to-show-strong-growth-trajectory-by-2034 2025-01-09T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/60139febcd6b3e01/candel-therapeutics-celebrates-phase-3-win-in-prostate-cancer-with-viral-immunotherapy 2025-01-09T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/67ce0e651b40540a/breakthrough-in-liver-cancer-treatment-with-immunotherapy 2025-01-09T06:37:43+00:00 hourly 0.9 https://trial.medpath.com/news/1a77744652564263/dyne-therapeutics-to-announce-new-clinical-data-from-achieve-trial 2025-01-09T06:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/3f52f6c3bdb1af5c/life-sciences-industry-report-forecasts-glp-1s-ai-and-digital-health-to-drive-innovation-in-2025 2025-01-09T06:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/b7ce7ecce9c9a1c2/ionic-liquids-enhance-skin-drug-delivery 2025-01-09T06:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/f79b3c2f47134c61/cosmo-pharmaceuticals-reports-progress-in-clinical-trials-and-strategic-growth-in-2024 2025-01-09T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/5d796724e33caef4/new-sarclisa-subcutaneous-formulation-meets-co-primary-endpoints-in-iraklia-phase-3-study-for-multiple-myeloma 2025-01-09T06:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/c56e47e6abf9aac5/gabapentin-doesn-t-increase-fall-risk-study-suggests 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9dc7e512c79a65fe/geographic-and-financial-barriers-limit-access-to-revolutionary-cell-and-gene-therapies-mckesson-report-reveals 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cb778d1eae6b9c9d/anacardio-raises-sek-205-million-and-reports-positive-phase-1b-data-of-ac01 2025-01-09T05:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/6fcb0c6cd7fe3827/bioanalysis-emerges-as-critical-foundation-for-precision-medicine-development 2025-01-09T05:42:43+00:00 hourly 0.9 https://trial.medpath.com/news/5e5f1572ad7964f9/bitterroot-bio-announces-positive-phase-1-study-results-for-brb-002-in-healthy-volunteers 2025-01-09T05:37:59+00:00 hourly 0.9 https://trial.medpath.com/news/71f4a40e050e0e9b/vivacelle-bio-to-showcase-phase-3-treatment-for-shock-and-trauma-at-bio-partnering-jpm-week-2025 2025-01-09T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/49bda5be0c8f7984/study-reveals-critical-gaps-in-uk-s-pharma-doctor-payment-disclosure-system 2025-01-09T05:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/969d0fa2e8f5e721/historical-medical-mistrust-and-safety-concerns-drive-covid-19-vaccine-hesitancy-among-black-women-study-reveals 2025-01-09T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5d781669d3139806/amd-enters-ai-drug-discovery-space-with-20m-investment-in-absci 2025-01-09T02:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/a8477c7191428964/chinese-firms-expand-solo-global-phase-iii-activity-including-us-sites 2025-01-09T02:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/390e5bc973b0f2b9/racial-and-gender-microaggressions-during-pregnancy-linked-to-elevated-postpartum-blood-pressure 2025-01-09T02:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/7e18546d4c7c1b79/fda-accepts-astellas-pharma-s-revised-snda-for-izervay-in-geographic-atrophy-treatment 2025-01-09T01:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/769648cb7c5d91e4/seikagaku-s-pain-drug-may-need-more-tailored-indication-rems-for-approval 2025-01-09T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/8ef23bc1e736e9f9/vir-biotechnology-s-promising-tce-oncology-assets-earn-buy-rating-from-joseph-stringer 2025-01-09T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/b53fd0ecc90203af/bms-partners-with-transgene-to-test-opdivo-tg4010-vaccine-combo-in-pd-l1-low-nsclc 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/095e48bbda36c484/rq-bio-s-kavigale-receives-positive-chmp-opinion-for-covid-19-prevention-in-immunocompromised-patients 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/86864af5432831a7/covid-19-vaccination-shows-strong-t-cell-response-in-multiple-myeloma-patients-on-lenalidomide-therapy 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/b7e17fadc7575dc2/combining-pi3kg-inhibition-with-radiotherapy-enhances-tumor-control-in-pancreatic-cancer 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/dfcf51678e109e22/innovative-clinical-trials-at-university-of-minnesota-offer-new-hope-for-glioblastoma-patients 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/00e30e2f1c41eb35/almirall-and-lilly-s-lebrikizumab-shows-promise-for-long-term-atopic-dermatitis-management 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/567a41f445937201/genascence-s-gene-therapy-shows-promising-safety-profile-in-phase-1b-osteoarthritis-trial 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/96c9eca36a0304a2/bonerge-announces-the-new-108-person-clinical-trial-exploring-skin-and-organ-anti-aging-innovations 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/60b93bb3a3812e8d/breakthrough-in-tuberculosis-treatment-new-antibiotic-btz-043-shows-promising-results 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/2f3af3721a784c79/sanofi-announces-breakthroughs-in-multiple-myeloma-and-ms-treatments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/be921e8bed3ec918/prospective-validation-of-oracle-in-lung-adenocarcinoma-prognosis 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/79109f820bd377bd/trisalus-life-sciences-announces-publication-of-pre-clinical-data-on-improved-delivery-of-embospheres-to-liver-tumors 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5cbca724e99c7ad/neoadjuvant-or-concurrent-atezolizumab-with-chemoradiation-for-locally-advanced-cervical-cancer 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c2a2c46a6abc013c/inovio-highlights-anticipated-2025-milestones-and-2024-key-accomplishments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a979eec262d0fc29/henlius-to-present-latest-clinical-data-of-hlx10-and-hlx22-at-2025-asco-gi 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/581eccbc31c67591/maat-pharma-sa-advances-in-gut-microbiome-driven-therapies-for-cancer-treatment 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/55420b84682bc6d9/europe-wide-study-aims-to-accelerate-depression-treatment-discovery 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/08dc9d61218230bf/clearpoint-neuro-achieves-fda-de-novo-marketing-authorization-for-smartflow-cannula 2025-01-08T23:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/fd0eb3649550cab6/aerwave-completes-first-in-human-study-of-lung-denervation-technology 2025-01-08T23:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/5c21964af50241b1/jpmorgan-raises-vir-biotechnology-price-target-to-14 2025-01-08T22:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/06c4ae3f7d51fbd4/viking-therapeutics-initiates-phase-2-trial-for-oral-vk2735-in-obesity-treatment 2025-01-08T22:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/fddab685f75deadc/cognition-therapeutics-ceo-to-present-at-upcoming-healthcare-conferences 2025-01-08T22:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/f398e0613b03df10/updates-on-ruxolitinib-combinations-for-mpns-from-ash-2024 2025-01-08T22:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/15fd795c5c96837d/scholar-rock-advances-sma-treatment-apitegromab-towards-commercialization 2025-01-08T21:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/2ae50eeead915606/zymeworks-announces-strategic-priorities-and-outlook-for-2025-and-2026 2025-01-08T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/76e27248423bbeac/uc-davis-health-pioneers-use-of-novel-pvad-system-in-cardiology 2025-01-08T21:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/4240c8ea823cd821/c-reactive-protein-identified-as-key-biomarker-for-hidradenitis-suppurativa-treatment-efficacy 2025-01-08T21:00:43+00:00 hourly 0.9 https://trial.medpath.com/news/3af75412bea8a943/dx-vx-advances-ferritin-based-universal-coronavirus-vaccine-to-phase-2-trials-following-promising-phase-1-results 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6c8887673571e1f4/tiziana-life-sciences-advances-in-immunomodulation-therapies-and-clinical-trials 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/86fb21f69228e22a/physiomics-project-and-cambridge-cognition-make-strides-in-medical-research 2025-01-08T20:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/d73a01cf476b8adc/tech-innovations-and-strategic-partnerships-highlight-ces-2025 2025-01-08T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/f1907e0b69d7d60b/testing-the-progress-of-precision-prostate-cancer-screening 2025-01-08T20:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/cb319b2acf16a0dc/cofactor-genomics-inc-announces-ceo-transition-and-highlights-clinical-trial-successes 2025-01-08T20:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/f19860c0ac8ca1d2/breakthrough-in-xenotransplantation-genetically-modified-porcine-heart-transplanted-into-human 2025-01-08T19:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/098728c700898f44/j-j-halts-varipulse-pulsed-field-ablation-cases-in-the-us 2025-01-08T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/716ecb1c9c3c96dc/disitamab-vedotin-and-toripalimab-show-promising-results-in-urothelial-carcinoma-treatment 2025-01-08T19:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/5f7929aeb51bdd3a/unc-breakthrough-research-on-food-allergy-drug-featured-in-national-geographic 2025-01-08T19:17:53+00:00 hourly 0.9 https://trial.medpath.com/news/75e34bb25b9cee83/hoth-therapeutics-addresses-market-rumors-and-updates-on-ht-001-clinical-trial-progress 2025-01-08T18:50:47+00:00 hourly 0.9 https://trial.medpath.com/news/ae9b1398241da664/maat-pharma-announces-positive-topline-results-from-ares-study 2025-01-08T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/31f282fc3b30d4fa/eirion-reports-positive-results-in-topical-hair-loss-therapy-trial 2025-01-08T18:01:46+00:00 hourly 0.9 https://trial.medpath.com/news/71cfd04b81b51595/adcentrx-initiates-phase-1a-b-study-for-adrx-0405-targeting-steap1-in-advanced-solid-tumours 2025-01-08T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6e94ea28085742fd/hoag-family-cancer-institute-advances-glioblastoma-treatment-with-innovative-clinical-trials 2025-01-08T17:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/a5642042b7a95e42/fda-proposes-sustained-5-weight-loss-to-establish-efficacy-of-new-antiobesity-medications 2025-01-08T17:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/eeca587996abd1a1/catalyst-pharmaceuticals-secures-patent-settlement-with-teva-extending-firdapse-market-exclusivity-until-2035 2025-01-08T17:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/b42b2a7957a1e68e/new-study-offers-hope-for-type-2-diabetes-patients-struggling-with-weight-loss 2025-01-08T17:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/7515caefcb817d0e/tenvie-raises-200m-for-brain-drug-r-d-sana-spikes-on-single-patient-s-results 2025-01-08T16:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/291d28974f471a66/boston-scientific-announces-acquisition-agreement-for-bolt-medical 2025-01-08T16:43:41+00:00 hourly 0.9 https://trial.medpath.com/news/9ad64e8dfcd92e65/curevo-vaccine-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f66491f42d04d2f/vir-biotechnology-stock-soars-on-prostate-cancer-trial-data 2025-01-08T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb9a07c32fbfe388/indaptus-therapeutics-highlights-2024-achievements-and-2025-outlook 2025-01-08T16:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/e9d0490ecc5fab34/suven-life-sciences-shares-surge-10-following-phase-1-clinical-trial-announcement 2025-01-08T15:42:05+00:00 hourly 0.9 https://trial.medpath.com/news/d80f7f3bd71898e6/sana-biotechnology-s-stock-receives-buy-rating-after-promising-phase-1-diabetes-treatment-results 2025-01-08T15:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/dada7d9e0ffb0a4e/biofrontera-inc-achieves-key-milestone-in-phase-3-study-of-ameluz-for-superficial-basal-cell-carcinoma-treatment 2025-01-08T15:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/e5e007b17f4bd56e/sana-biotechnology-s-breakthrough-in-type-1-diabetes-treatment 2025-01-08T15:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/6a806a1eb95ffc85/geron-stock-rallies-more-than-60-in-a-year-here-s-why 2025-01-08T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/0ca73bf12b212478/mbx-biosciences-reports-positive-phase-i-trial-results-for-glp-1ra-in-treating-hypoglycaemia 2025-01-08T15:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/c93930fa781a395d/updates-on-clinical-trials-funding-and-shelved-projects-in-ophthalmology 2025-01-08T15:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/08192c116c73b2be/moma-therapeutics-advances-in-precision-medicine-with-new-parp1-inhibitor-and-clinical-updates 2025-01-08T14:54:04+00:00 hourly 0.9 https://trial.medpath.com/news/8c69e75312036de1/5-questions-novo-nordisk-must-answer-to-drive-its-stock-higher 2025-01-08T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/865e7aa7f13545b4/autobahn-therapeutics-initiates-phase-2-trial-for-abx-002-in-bipolar-depression-treatment 2025-01-08T14:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/86c27ea51359f7df/fda-grants-orphan-drug-designation-to-cnp-104-for-primary-biliary-cholangitis 2025-01-08T14:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/7e4a5641ced55f54/j-j-s-posdinemab-granted-fda-fast-track-designation-for-alzheimer-s-treatment 2025-01-08T14:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/85a178c2b4ee1a7c/lb-pharmaceuticals-reveals-phase-2-schizophrenia-data 2025-01-08T14:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/4f1528a0dab0b2ef/anokion-announces-positive-symptom-data-from-its-phase-2-trial-evaluating-kan-101-for-celiac-disease 2025-01-08T14:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/94b5487589058e35/quanta-receives-fda-ind-clearance-for-qtx3544-and-advances-kras-inhibitor-pipeline 2025-01-08T14:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/f60cb0c10c3c565e/community-engagement-methods-in-fm-tips-trial-to-be-discussed-at-pct-grand-rounds 2025-01-08T14:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/312c7edd241addd6/inpatient-treatment-of-suicidality-a-systematic-review-of-clinical-trials 2025-01-08T14:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/65dcb51c45234139/sellas-advances-cancer-drug-trials-with-key-2025-milestones-in-sight 2025-01-08T14:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/2ddcac074717cffe/avidity-biosciences-accelerates-path-to-first-drug-approval-and-expands-leadership-for-2025 2025-01-08T14:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/1d7229bf5254248b/taiho-oncology-to-present-real-world-data-on-colorectal-cancer-treatments-at-asco-gi-2025 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/84784946a932c61d/fda-to-decide-on-agios-request-for-expanded-approval-of-pyrukynd-in-thalassemia-by-september-7 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0374b5f485c370ca/igc-pharma-s-calma-trial-triples-alzheimer-s-patient-recruitment-with-ai-powered-strategy 2025-01-08T13:55:48+00:00 hourly 0.9 https://trial.medpath.com/news/4bfcd33a61caf191/foresight-diagnostics-sets-strategic-goals-for-2025-following-a-year-of-significant-achievements 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/49cb98cbc1a97211/bexion-pharmaceuticals-to-present-bxq-350-study-findings-at-asco-gi-2025 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb39a8f31b3da69d/novel-updates-in-second-line-therapies-for-lr-mds 2025-01-08T13:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/eced220b646f43c4/formycon-and-fresenius-kabi-canada-receive-health-canada-s-approval-for-fyb202-otulfi 2025-01-08T13:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/378a76396a85f5a3/vir-biotechnology-reports-encouraging-phase-1-data-for-two-cancer-drug-candidates 2025-01-08T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/94510b04dff17772/compass-therapeutics-advances-oncology-pipeline-with-new-drug-candidates-and-clinical-trials 2025-01-08T13:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/2ebea930bd345828/vigeneron-receives-fda-rare-pediatric-disease-designation-for-vg901-and-advances-in-phase-1b-retinitis-pigmentosa-trial 2025-01-08T13:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/473658e2813d8e33/ensysce-biosciences-highlights-2024-achievements-and-future-plans-in-annual-shareholder-letter 2025-01-08T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf91daa393b3cf24/replimune-advances-rp2-development-program-with-clinical-trials-for-melanoma-and-liver-cancer 2025-01-08T13:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/00bd1c8adf500cc7/advancements-and-challenges-in-cancer-care-and-treatment-planning 2025-01-08T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/0c07a996ff8868ec/denali-therapeutics-receives-fda-breakthrough-therapy-designation-for-tividenofusp-alfa-in-hunter-syndrome-treatment 2025-01-08T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/5650efd3c60222ea/viva-biotech-s-portfolio-companies-showcase-significant-r-d-progress 2025-01-08T13:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/26a1ed5587ccb886/tinivo-2-trial-highlights-challenges-in-ici-retreatment-for-advanced-rcc 2025-01-08T13:00:32+00:00 hourly 0.9 https://trial.medpath.com/news/4e111abe498fb140/ocular-therapeutix-to-present-corporate-update-at-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3e27dd14cdefdebb/asher-bio-and-amgen-collaborate-on-clinical-trial-for-es-sclc-treatment 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c52b9a832928208/denali-therapeutics-spinout-secures-200m-in-funding 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aa8f3945ff77dd3d/sensei-biotherapeutics-announces-key-milestones-and-updates-for-solnerstotug-sns-101 2025-01-08T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/7fa3eadc67385792/achieve-life-sciences-reaches-critical-milestone-in-orca-ol-clinical-trial-for-cytisinicline 2025-01-08T12:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/9e3db0b07ea11d57/edap-announces-first-pancreatic-cancer-patient-treated-with-proprietary-hifu-technology 2025-01-08T12:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/702312d88e3cb372/arch-biopartners-receives-ethics-approval-for-phase-ii-trial-of-lsalt-peptide-targeting-cs-aki 2025-01-08T12:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/4d4b3044779b6c2e/biodesix-s-nodify-cdt-blood-test-shows-promise-in-lung-cancer-detection-study 2025-01-08T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/5430f459a1c05cd5/marengo-s-invikafusp-alfa-receives-fda-fast-track-designation-for-advanced-colorectal-cancer-treatment 2025-01-08T12:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/22fdfaac38bfc7c0/compugen-advances-com503-into-phase-1-clinical-trial-for-advanced-solid-tumors 2025-01-08T12:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/bb0b1ac0ac31e4f9/kamada-projects-continued-growth-with-2025-financial-guidance-and-strategic-expansions 2025-01-08T12:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/76556dc108ea5e2b/stoke-therapeutics-receives-buy-rating-based-on-strong-phase-3-trial-design-and-early-results 2025-01-08T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/91c7d281fa228d74/equivalence-confirmed-ct-p41-paves-the-way-for-affordable-osteoporosis-care 2025-01-08T12:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/b475b6eb1c063127/biostem-technologies-launches-clinical-trial-to-demonstrate-therapeutic-benefits-of-bioretain-technology-in-treating-diabetic-foot-ulcers 2025-01-08T12:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/a2cf26195607dafe/moonlake-initiates-three-new-clinical-trials-for-sonelokimab-in-dermatology-and-rheumatology 2025-01-08T12:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/e1e4c3ea255627bc/ai-driven-clinical-alert-system-shows-10x-improvement-in-suicide-risk-screening-rates 2025-01-08T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/2b21b2fd28f4b94a/lb-pharmaceuticals-announces-positive-topline-results-for-lb-102-in-schizophrenia-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2799c432b740b29c/long-acting-injectable-antipsychotics-show-promise-in-adolescent-bipolar-mania-management 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/488c25d92ff62685/sana-biotechnology-s-revolutionary-breakthrough-in-type-1-diabetes-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a7fdb8a8ae73ffcb/renovorx-advances-targeted-cancer-therapy-with-tamp-platform 2025-01-08T11:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/1a83d0ad8d546a29/moonlake-immunotherapeutics-affirmed-with-buy-rating-for-strategic-clinical-expansion 2025-01-08T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/15118b7b12f4a590/nephrology-month-in-review-december-2024 2025-01-08T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b63f466ffbfa46aa/nextgen-class-of-2025-and-m-a-uptick-predicted 2025-01-08T10:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/89876a196b173bab/alzheimer-s-drug-discovery-foundation-invests-record-10m-in-alamar-biosciences-for-blood-based-diagnostic-platform 2025-01-08T10:47:11+00:00 hourly 0.9 https://trial.medpath.com/news/0543879b94f3a23b/sana-biotechnology-s-up421-therapy-shows-promising-results-in-type-1-diabetes 2025-01-08T10:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/d81ef41f41445182/zhengye-biotechnology-raises-6-9-million-in-ipo-to-expand-veterinary-vaccine-portfolio 2025-01-08T10:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/e6e212eaf793d8c3/iros-and-halia-therapeutics-launch-pioneering-obesity-clinical-trial-in-uae 2025-01-08T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/7541bd22f72e9525/positive-fda-feedback-for-phase-ii-trial-of-tiprelestat-in-pulmonary-arterial-hypertension 2025-01-08T09:41:32+00:00 hourly 0.9 https://trial.medpath.com/news/6cdb569bf5dc5944/micron-biomedical-advances-needle-free-vaccine-technology-with-43-million-in-funding 2025-01-08T09:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/8a414acb5ad488fa/comparative-study-on-cefoxitin-administration-methods-for-preventing-surgical-site-infections 2025-01-08T09:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/fa52940f8c1a051d/alyssum-therapeutics-expands-series-a-funding-with-femhealth-ventures-participation 2025-01-08T09:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/39c1c3720be2746a/senate-investigation-reveals-concerning-impact-of-private-equity-ownership-on-healthcare-quality-and-safety 2025-01-08T09:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/34ba57eaf98d6a3f/experienced-industry-leader-dr-joerg-moeller-appointed-as-chief-executive-officer-of-antag-therapeutics 2025-01-08T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/2071b7b8a155a2af/physiomics-plc-announces-approval-for-predict-onc-clinical-trial 2025-01-08T09:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/c161bec22d72b2a3/oxford-s-novel-blood-test-shows-95-accuracy-in-early-cancer-detection-across-six-cancer-types 2025-01-08T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e7f6a87221bbcd6/new-prostate-cancer-imaging-technique-shows-promising-results-in-clinical-trials 2025-01-08T08:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/1a9b9ec8095fcae3/aca-enrollment-hits-historic-23-6-million-as-enhanced-subsidies-face-2025-expiration 2025-01-08T08:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/1e0078c26cd9d9b8/global-workplace-wellness-market-sees-substantial-growth 2025-01-08T08:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/b07e34225dd72f1c/genmab-s-rybrevant-lazcluze-combination-shows-superior-survival-benefits-in-egfr-lung-cancer 2025-01-08T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/17d18a2d1ca27b3d/china-s-nmpa-approves-padcev-in-combination-with-keytruda-for-advanced-urothelial-cancer 2025-01-08T07:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/1d3e4718748c630f/aer-therapeutics-doses-first-patient-in-phase-2-clinical-trial-for-copd-treatment 2025-01-08T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/7846e17efd7be8c6/cambridge-cognition-s-cantab-plays-key-role-in-schizophrenia-drug-approval 2025-01-08T07:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/1991796a173c4670/bioinvent-announces-promising-data-for-bi-1910-as-single-agent-from-phase-1-study-in-solid-tumors 2025-01-08T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/afc4c650fabd0ca8/proteomic-analysis-reveals-new-insights-into-semaglutide-s-mechanism-of-action 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/11fd91c120b260b2/allurion-s-audacity-trial-achieves-one-co-primary-endpoint-misses-another 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/11eb4a25f0171a0f/25-of-patients-recruited-in-guard-therapeutics-phase-2b-pointer-study 2025-01-08T07:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/6e6dd048ba0cd0b7/global-study-projects-mixed-trends-in-childhood-atopic-dermatitis-through-2050 2025-01-08T07:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/09c0fd9d574e479c/azafaros-receives-orphan-drug-designations-for-nizubaglustat-in-gm1-gangliosidosis-treatment 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/348a234194ec44ee/bioinvent-reports-promising-early-results-from-triple-combination-therapy-for-non-hodgkin-s-lymphoma 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ab1253a10e122518/ryght-ai-partners-with-qps-holdings-to-transform-clinical-trial-operations-using-ai-technology 2025-01-08T06:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/98592565c593d002/in-home-rehabilitation-shows-promise-despite-healthcare-system-barriers 2025-01-08T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/395002c84c7135c0/yale-surgeon-scientist-secures-fda-orphan-drug-designation-for-pembrolizumab-in-rare-respiratory-disease 2025-01-08T05:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/d0a1d5d5f875434a/hormone-replacement-therapy-and-cancer-survival-a-longitudinal-cohort-study 2025-01-08T05:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/200374095d2dcb7e/merck-says-its-hpv-vaccine-for-men-was-approved 2025-01-08T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/1586e6ea00417c50/corbus-pharmaceuticals-to-present-crb-701-clinical-data-at-asco-gu-2025 2025-01-08T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c62fc49b328f4436/mifepristone-as-weekly-contraceptive-performs-beyond-expectations-in-b-clinical-trials-b 2025-01-08T04:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/cb9a915fd170c89b/ocugen-q3-2024-earnings-highlight-clinical-progress-in-gene-therapy 2025-01-08T03:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/79f37f5dec15e200/galapagos-announces-strategic-split-and-restructured-gilead-partnership-in-major-corporate-overhaul 2025-01-08T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/cfb28d696d79288f/nicklaus-childrens-hospital-advances-pediatric-cancer-treatment-with-targeted-therapy 2025-01-08T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adf67e58a9a150f3/arrowhead-pharmaceuticals-cfo-kenneth-myszkowski-sells-893095-in-stock 2025-01-08T02:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/ef0eb645cd2140c4/hoth-s-phase-iia-derma-data-in-cancer-b-patients-b-propels-its-stock-bioworld 2025-01-08T02:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/37aa251e68e013ff/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-b-clinical-b-utility-of 2025-01-08T02:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/af188d923ed2bccb/advancing-immunotherapy-for-glioblastoma-duke-research-blog 2025-01-08T00:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/5ed09ff1c2bebc96/fda-decision-on-atara-biotherapeutics-tab-cel-expected-soon 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f16616f429ce0a86/shorla-oncology-announces-u-s-food-and-drug-administration-fda 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/192228a3c1d21920/new-4-month-tb-treatment-regimen-shows-effectiveness-comparable-to-standard-6-month-regimen 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c18bf595daee5f18/ferring-s-gut-microbiome-drug-shows-promise-in-phase-3-trial-for-c-diff 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/43c632df4f4c5a59/breakthroughs-and-partnerships-in-medical-technology-and-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7c6b250defabbb4/fda-approves-immunitybio-s-bladder-cancer-drug-after-second-review 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8297ba80b5b1541/biomarin-s-roctavian-receives-conditional-approval-in-europe-for-haemophilia-a-treatment 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/58723b65ead0d9b6/patient-reported-qol-outcomes-of-initial-cll-treatments-highlighted-at-ash-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3ca6351060a39018/avadel-reports-significant-growth-in-lumryz-sales-and-patient-adoption-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f2ea04d4b08cedd/comparative-evaluation-of-high-flow-nasal-cannula-hfnc-vs-conventional-oxygen-therapy-cot-in-infants-after-non-cardiac-surgery 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c39d08463075160/heart-device-impresses-fda-stryker-acquires-inari-medical 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/33e8f95edf984e3d/fda-s-new-guidance-on-psychedelic-therapy-clinical-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0401e885ab4e036f/breakthroughs-in-non-small-cell-lung-cancer-research-highlight-new-treatment-pathways 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ed8442e23039c1be/modified-consent-procedures-may-enhance-psychedelic-trials-validity 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/92e23ba8ba33c04e/class-action-lawsuit-filed-against-bioage-labs-inc-following-discontinuation-of-azelaprag-trial 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/29fb3d836c0e5e56/6-of-seniors-depressed-adhd-and-hormones-novel-antipsychotic-eases-schizophrenia 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8e4b719ba9054c59/uab-clinical-trials-offer-opportunities-for-participation-in-groundbreaking-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9af38a138234dc39/glp-1-receptor-agonists-linked-to-reduced-surgical-complications-in-diabetic-patients 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8591b99adee2a33e/hansa-biopharma-announces-key-developments-and-achievements-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2e6e9739951e87cf/celgenes-multiple-myeloma-orphan-drug-gets-fda-approval 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adf3598a2c2f7258/synairgen-advances-to-phase-3-trial-of-inhaled-covid-19-treatment-sng001 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d9a4caf72b78b461/fda-approves-phase-1-2-clinical-trial-for-rec-4539-in-small-cell-lung-cancer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f82eb6f8a4eb8e4a/centessa-pharmaceuticals-appoints-stephen-kanes-md-phd-as-chief-medical-officer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6448e9666c993ca7/basilea-pharmaceutica-reports-progress-and-future-plans-for-its-r-d-portfolio 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c7874b3ef1ae5d7/fda-fast-tracks-neurovive-s-traumatic-brain-injury-drug 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4a5290ec5c48f3d8/alebund-pharmaceuticals-completes-series-c-financing-of-rmb-550-million 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fadf5f685c890643/modified-consent-procedures-may-enhance-psychedelic-drug-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c6c11f69a5182d1f/jasper-therapeutics-announces-promising-results-from-beacon-study-for-briquilimab-in-chronic-spontaneous-urticaria 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3e5fc80116df4f8f/abbvie-expands-ophthalmology-pipeline-with-regenxbio-gene-therapy-deal 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5fa5edfd825024c9/trametinib-shows-breakthrough-results-in-children-with-severe-genetic-heart-condition 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e7920c2e41946f90/regeneron-and-inovio-to-aim-immunotherapy-at-hard-to-treat-brain-tumour 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/559eb5f237c5b72c/targeting-cd30-in-diffuse-large-b-cell-lymphoma-where-does-it-fit-in 2025-01-07T23:59:22+00:00 hourly 0.9 https://trial.medpath.com/news/e3468ac77042dcd3/solid-biosciences-revolutionary-dual-route-gene-therapy-for-friedreich-s-ataxia-gains 2025-01-07T23:47:58+00:00 hourly 0.9 https://trial.medpath.com/news/d9d8bc4a02d267f9/treating-brain-cancer-with-immunotherapy-stanford-medicine 2025-01-07T23:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/6f407b5ccda36f91/b-precision-medicine-b-biotech-maze-therapeutics-files-for-a-100-million-ipo 2025-01-07T22:53:02+00:00 hourly 0.9 https://trial.medpath.com/news/f7d566b7c1361866/eoi-international-junior-gender-consultant-for-west-africa-ahgc 2025-01-07T21:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/519dfc02ddbdea10/fda-issues-new-guidance-on-sex-and-gender-considerations-in-medical-device-and-drug-development 2025-01-07T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/8f8b4d195b186722/cytomx-therapeutics-swot-analysis-oncology-biotech-s-stock-faces-pivotal-year 2025-01-07T21:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/8d0ebee7440411f1/a-single-center-single-arm-prospective-open-label-and-comparative-trial-to-evaluate-the-nature 2025-01-07T20:59:56+00:00 hourly 0.9 https://trial.medpath.com/news/faf0f91c81185a82/for-the-record-january-7-2025-dct-guidance-revised-short-form-policy-more 2025-01-07T20:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/dc4093b50eb29c3b/biopharma-layoffs-increase-by-3-in-2024-fierce-biotech-reports 2025-01-07T20:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/976bb78eb2a25e2c/stereotactic-body-radiation-may-improve-survival-in-liver-cancer-subset 2025-01-07T20:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b8593953d220249/who-to-develop-lenacapavir-and-hiv-testing-guidelines-managed-healthcare-executive 2025-01-07T20:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/2e76e2fa5a362fec/fda-approvals-expand-initial-treatment-options-for-multiple-myeloma-national-cancer-institute 2025-01-07T18:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/55ae8cf91e6bb9b3/prucalopride-tablets-for-chronic-idiopathic-constipation-b-launches-b-approved-for-180-day 2025-01-07T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/6901c835b0d0e5a8/myriad-genetics-md-anderson-forms-5-year-strategic-alliance 2025-01-07T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/cdcf3b338748a2b4/wegovy-and-zepbound-tipped-to-fuel-20b-boom-in-heart-failure-market-fierce-pharma 2025-01-07T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/6713eb14d1d66332/francis-medical-secures-80m-series-c-funding-for-innovative-water-vapor-ablation-technology 2025-01-07T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/22c8ae040c4bc815/dr-deangelo-on-the-b-fda-approval-b-of-blinatumomab-consolidation-in-cd19-ph-b-all 2025-01-07T15:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/b97d5222ae07b33c/structure-therapeutics-earns-buy-rating-for-innovative-oral-obesity-treatments 2025-01-07T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/a955b0ca1d10c6d5/abbvie-advances-cns-gene-therapy-with-capsida-through-40-million-option 2025-01-07T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/7dffcdc50d70e689/jefferies-upgrades-instil-bio-highlighting-potential-of-syn2510-in-cancer-treatment 2025-01-07T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/ef045f99b5719cab/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/22d7feb412f12f9a/short-course-radiation-therapy-shows-promise-for-older-glioblastoma-patients 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4a47a3b226b4ef31/china-greenlights-first-stem-cell-therapy-on-mixed-clinical-findings-citeline 2025-01-07T13:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/c2a96328e7c85d91/sling-therapeutics-appoints-andrew-guggenhime-to-its-board-of-directors 2025-01-07T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/9eebb015975c2f6b/marvel-biosciences-secures-funding-for-phase-1-clinical-trials-of-mb-204 2025-01-07T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/a716b6b8786398b5/analyst-recommends-buying-arcturus-therapeutics-shares-due-to-h5n1-vaccine-demand 2025-01-07T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/565c075aaa6eaffc/promising-phase-1-2-results-for-acelyrin-s-lonigutamab-support-buy-rating 2025-01-07T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/701ba50ffa1c8081/xeltis-announces-completion-of-enrolment-in-eu-pivotal-trial-for-axess-and-prepares-for 2025-01-07T09:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/8557e604bd992a76/bial-announces-first-patient-out-in-its-phase-2-clinical-trial-of-bia-28-6156-biospace 2025-01-07T09:01:28+00:00 hourly 0.9 https://trial.medpath.com/news/bc73f6dcb52f2839/real-world-studies-show-improved-survival-rates-in-pediatric-aml-transplantation 2025-01-07T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e25e6ecba085684f/precision-medicine-and-value-based-cancer-care-navigating-implementation-challenges-in-academic-and-community-settings 2025-01-07T08:50:38+00:00 hourly 0.9 https://trial.medpath.com/news/2f0170c17a9431c6/pacira-announces-fda-clearance-for-new-back-pain-treatment 2025-01-07T08:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/fcab565c7d4c03c3/new-publication-highlights-safety-and-potential-benefits-of-redosing-diamyd-r-precision 2025-01-07T08:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/7d86d456682c48d1/qlife-provides-update-on-operational-progress-in-china-qlife-holding-ab-cision-news 2025-01-07T08:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/3412bb8278079d06/qnovia-inc-announces-first-patient-dosed-in-u-s-phase-1-study-for-respirxtm-nicotine-inhaler 2025-01-07T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/962708c088fb0924/drug-pricing-reform-shows-promise-as-2000-medicare-out-of-pocket-cap-set-for-2025 2025-01-07T07:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/999a452e61bc7d3b/next-lifts-full-year-guidance-gsk-drug-gets-new-breakthrough-designation-sharecast-com 2025-01-07T07:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/655afeb39404bd50/cormedix-inc-announces-preliminary-fourth-quarter-2024-results-and-provides-business-update 2025-01-07T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/34eaf1b9b1d54ecb/opthea-reports-positive-phase-1b-dme-trial-results 2025-01-07T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/203445753fc4176c/4sc-ag-4sc-announces-update-relating-to-resminostat-s-kinselby-marketing 2025-01-07T07:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/75aa89228c7e61fc/evolution-of-managed-care-three-decades-of-healthcare-transformation-and-future-outlook 2025-01-07T07:00:20+00:00 hourly 0.9 https://trial.medpath.com/news/fbe738c3bd5b0e86/hope-therapeutics-to-acquire-kadima-neuropsychiatry-institute-as-flagship-for-global-interventional-psychiatry-network 2025-01-07T06:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/ec41995725a4db9e/global-dna-sequencing-market-set-to-reach-106-billion-by-2034-driven-by-next-generation-technologies 2025-01-07T06:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/9578918ac2ea2176/interius-biotherapeutics-expands-phase-1-clinical-trial-of-int2104-into-europe 2025-01-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d6ce1e7c8b4b89a7/alivegen-receives-fda-orphan-drug-designation-for-alg-801-for-pulmonary-arterial-hypertension 2025-01-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/88a121836a3f78f6/abl-bio-s-anticancer-drug-candidate-emerges-as-us-partner-s-core-pipeline-kbr 2025-01-07T04:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/91b64b79c96c1943/vertex-partners-with-orna-in-700m-deal-to-develop-in-vivo-gene-therapies-for-blood-disorders 2025-01-07T04:19:51+00:00 hourly 0.9 https://trial.medpath.com/news/cbc775f2a5c275d6/cspc-pharmaceutical-s-syh2059-tablets-gain-clinical-trial-approval-in-china 2025-01-07T03:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b91801ea0cdb54c/candid-therapeutics-and-wuxi-biologics-forge-925m-deal-for-novel-t-cell-engager-development 2025-01-07T03:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/2b821d0724c08eef/msd-acquires-wuxi-biologics-irish-vaccine-facility-for-500m-amid-regulatory-pressures 2025-01-07T03:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/da18a7af82746f8b/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for 2025-01-07T01:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/67da6587b2f12917/cell-gene-therapies-pink-sheet-citeline 2025-01-07T01:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/765d1d01ad8ef2c8/the-registrational-clinical-data-of-glecirasib-was-published-in-nature-medicine 2025-01-07T00:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/418984293ec2f32b/regeneron-expands-gene-therapy-portfolio-with-decibel-therapeutics-acquisition 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d2f41a794a15cccf/iterum-therapeutics-nasdaq-itrm-stock-quotes-forecast-and-news-summary 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1851cca8bcc6e994/regenxbio-expands-mps-i-gene-therapy-trial-after-initial-data-review 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb2da4375b8254bf/fda-rejects-cytokinetics-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6d5f05b8933dfa94/eu-approves-enhertu-for-her2-low-breast-cancer-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/02a27d97f692408e/h-c-wainwright-cuts-acelyrin-stock-target-keeps-neutral 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0e5579f940d52a8c/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d50b384f89b20b99/az-s-antibody-first-to-be-cleared-by-fda-for-covid-prevention 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c42ac10a0b3a46c3/mammaprint-assay-identifies-subgroup-benefiting-from-extended-letrozole-therapy-in-early-stage-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc0c1b3eb1e56ba2/opko-health-s-modex-therapeutics-announces-epstein 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4dd3147d78deb9c6/fda-reveals-diversity-action-plan-guide-for-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c0e37d0b877f1e8e/beyond-covid-19-mrna-vaccines-aim-to-revolutionise-cancer-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4dd51e68fb6e399/amgen-and-astrazeneca-highlight-tezspire-s-potential-in-copd-treatment-despite-trial-outcome 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/96c1963521691bc2/advances-in-nephrology-breakthroughs-in-kidney-transplantation-and-disease-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3ca62c9b3fce2b89/pfizer-s-haemophilia-b-gene-therapy-meets-phase-3-primary-endpoint 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/04b09083870e19d0/novartis-app-could-revolutionise-ophthalmic-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2856f1116a7233b5/halda-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8bb251f1fdad05c/fda-approves-emrosi-for-rosacea-in-adults-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f40e436878a86f71/rsv-vaccines-add-guillain-barre-warning-conexiant 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1d61dacb76b44198/breakthroughs-and-challenges-in-gene-therapy-a-2024-overview 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c5a10112aa1dbb62/pfizers-rsv-shot-clears-fda-adcomm-now-its-gsks-turn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e214fce806824126/takeda-looks-to-digitise-drug-trials-with-koneksa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9fc9529848c1c06c/applied-tx-craters-as-fda-rejects-lead-product-candidate 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8050fc757cdc59d9/bright-minds-biosciences-appoints-pharmaceutical-leader 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/597e76957fe90d5c/raphael-pharmaceutical-announces-positive-proof-of 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/74fae6deacb6e3f3/agios-up-as-fda-gives-thermo-fisher-glioma-test-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eff4f2b7c526cb9b/recursion-announces-two-key-investigational-oncology 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/00f61f5cc9f6b9f1/study-points-to-weaknesses-in-fda-accelerated-approval-path 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc29f763722b9949/press-release-six-month-data-from-alfapump-r-pivotal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3e99a640738a99c7/fda-advisers-reject-new-use-for-pacira-nerve-block 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/37e272aa633baca1/vyloy-zolbetuximab-uses-dosage-side-effects-warnings-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3be6809940fec5e9/novel-btk-degrader-nx-5948-yields-high-response 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5727eab0c93ae48d/car-t-cell-therapy-industry-surges-to-141-2-billion-in-funding-as-clinical-success-drives-investment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/91a17a553d836223/fda-gives-pfizer-s-group-b-strep-vaccine-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4f3f399182a20088/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e9f29371de453392/phase-3-trial-win-sets-up-rare-disease-drug-filing-for-csl 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec08fb6d570c0f68/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d3ec1a4a0e802502/actuate-therapeutics-receives-ema-orphan-medicinal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3b666fce11434cc2/bayer-third-indication-requested-in-china-for-nubeqa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc83d9f3825ebe08/breakthrough-in-xenotransplantation-genetically-engineered-pig-hearts-show-promise-for-human-transplantation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/04e2ccee6c15427f/eqs-news-immunic-highlights-2024-accomplishments-and 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/62ec9ca9e5030d58/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6946ff297ef04c78/how-effective-are-glp-1-meds-for-weight-loss-in-people-without-diabetes 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/480a0c25031b795e/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/23ddad85403f9e42/simpson-interventions-announces-both-ide-approval-from 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b735d395b741b79/egg-maturation-supported-by-stem-cells-results-in-first-live 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/602885507b5a0e58/bicycle-therapeutics-partners-with-cancer-research-uk-for-cancer-treatment-development 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1058f1aab3cebbd4/immunogen-elahere-wins-accelerated-fda-approval-for-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/51b1bfd2000bddae/dimerix-has-entered-into-a-development-and-license-agreement-for-japan 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a4305908421a6104/odronextamab-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/69107f37bcc8def0/us-fda-accepts-nda-filing-for-bi-s-nintedanib 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ccc3854b30cdc20f/fda-fast-tracks-gsks-chronic-hep-b-therapy-bepirovirsen 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a0a917f35c18378a/bofa-cuts-denali-therapeutics-stock-target-as-als-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4fffe323875b1cc7/google-s-anti-aging-company-just-released-disappointing 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7c1c664f4298c7b2/senseera-raises-7-1-million-seed-round-led-by 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cac6e1a8a7a41d82/pmv-pharmaceuticals-inc-pmvp 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d33c7f9be5744162/bright-minds-biosciences-appoints-stephen-collins-m-d-ph-d-as-chief-medical-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e0b89a1d66242adc/tune-therapeutics-receives-approval-to-initiate-clinical 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/de3289afa513a567/roche-scores-adjuvant-lung-cancer-approval-for-tecentriq 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1270da24e87e52bd/ucb-chalks-hidradenitis-suppurativa-as-fifth-indication-for-bimzelx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/69f47ecad6864006/could-crispr-cure-hiv-us-biotech-excision-raises-60m-to-find-out 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/293fd3d803f6fdd0/january-7-2025-after-tough-year-moderna-ceo-confronts 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/835d4d382fbe2812/carrots-show-potential-in-diabetes-treatment-through-gut-microbiome-alteration 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/869a75968ee18299/lundbeck-and-takeda-seek-fda-approval-for-antidepressant-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/439d28408d081049/alkeus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/583bf8b551362b0c/fda-sets-november-review-date-for-j-j-s-multiple-myeloma-car-t-cilta-cel 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7795f053989da014/regeneron-and-lilly-post-new-data-backing-covid-antibody-cocktails 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c39a769787fe6efd/fda-turns-down-satsumas-nasal-migraine-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b4ae9103f08f9e0b/akero-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9bc37e55776bb0a1/accurkardia-receives-fda-breakthrough-device-designation-for-ai-powered-hyperkalemia-detection-solution-using-lead-i-ecg-data 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6ccd91e25b5ffe1c/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3e9b63afb7eb1e60/fda-gives-abbvie-s-c-met-lung-cancer-adc-a-breakthrough-tag 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6ee486c3e4cae6c0/u-s-fda-approves-aop-health-s-rapiblyktm-landiolol-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6e08df1ba362b0e/fda-approves-new-heart-failure-use-for-az-s-farxiga 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/19f8aa03e412906a/tesaro-s-niraparib-approved-in-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/39201aa79f29dee0/geron-corporation-gern-stock-price-news-quote-history-yahoo-finance 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a8089c3150af9515/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c00aaaf407beb135/metseras-touts-powerful-weight-loss-results-again 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/46cd8bf65c7c30ed/neurotech-fda-update-on-nt-501-mactel-treatment-obn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4b9c7b0bca2b3f20/u-s-fda-granted-priority-review-to-dizal-s-sunvozertinib-new-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e168403be2f8ac43/pila-pharma-ab-announces-preclinical-preclinical-proof-of-concept 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3768f86ba6d988bc/rapt-therapeutics-announces-initiation-of-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/caa2e98539968bd5/inside-esmo-2024-treatments-trials-and-top-hcps-on-social-media 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b29d28c0c0f12c36/cassava-sciences-provides-a-business-update 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/71ac5f5736499dfa/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ea7fa274725fc796/maia-biotechnology-inc-maia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8e6a2d54f3dd2616/luspatercept-lenalidomide-combo-demonstrates-safety 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdb15d48ac129e41/second-time-lucky-at-fda-for-citius-lymphoma-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ee388809c2b86d94/immuneering-reports-positive-phase-2a-data-for-imm-1-104 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/446c2fe56236170f/restem-receives-fda-fast-track-designation-for-restem-l-for-idiopathic-inflammatory-myopathy 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/21b4a3b8b323d892/verona-pharma-reports-strong-ohtuvayretm-launch-and-provides-preliminary-fourth-quarter-and-full-year-2024-financial-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bfe653685f02affc/single-dose-hpv-vaccine-shows-promise-in-long-term-cervical-cancer-prevention-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7457b2e6af0446bb/verismo-therapeutics-announces-strategic-partnership 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1eb451bf760b88cc/lin-bioscience-inc-lin-bioscience-receives-u-s-fda-fast-track-designation-for-lbs-007 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ca251768f8acc80d/phase-ii-trial-shows-ambroxol-safe-but-ineffective-for-parkinson-s-disease-dementia-cognitive-symptoms 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/91c007098e503fa9/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a1cb9742fd1006f0/baxter-alzheimers-drug-fails-to-meet-phase-3-endpoints 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f9f8fdc9314fa0ac/som-s-ai-discovered-drug-shows-promise-in-huntington-s-disease 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aea628410920a9a9/govorestat-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/15813c0ef7d10344/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/497b0918fc6f2a1e/johnson-johnson-medtech-temporarily-pauses-u-s-varipulse-cases 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ce5d960bdba89be5/fda-clears-ai-that-detects-heart-failure-using-a-stethoscope 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/87121d96bbd0a625/brainchild-bio-inc-to-clinically-advance-bcb-276-an 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1aefbd6a0192bd9d/j-j-says-lung-cancer-combo-improves-survival-more-than-standard-of-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acf877925f15061d/alleviant-medical-wins-fda-ide-breakthrough-nods-for-no-implant-heart-failure-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/574b66f5a925a0c2/news-for-the-cardiac-and-vascular-medtech-and-biotech 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ad2a92affe1d757/fda-removes-leash-from-verzenio-in-early-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf84242102e1bb63/january-2025-1stoncologytm-cancer-intelligence-service 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c451efceffe8793f/wt-7-shows-acceptable-safety-profile-in-relapsed 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a3aa44ed112366c7/homozygous-familial-hypercholesterolemia-treatment-market-to-surge-by-2034 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d41e16b6e60c4763/aldeyras-reproxalap-for-dry-eye-disease-accepted-by-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/019d2220dce1a3b9/fda-roundup-january-7-2025 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1afedb295f3bfd28/fda-grants-priority-review-of-astellas-zolbetuximab-bla 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/15f2255c627e58af/gsk-s-parp-drug-zejula-approved-in-wider-ovarian-cancer-population 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1389b88e963a9457/onl-therapeutics-strengthens-leadership-with-appointment-of-penny-fleck-as-chief-development-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a095b9d0441b2f48/verona-to-test-copd-hopeful-ensifentrine-in-covid-19-patients 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc4fb1dfae3feb4b/fire1-raises-120m-to-develop-its-heart-failure 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c672c6efcaa176a/fda-approves-bayer-merck-co-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/db53a4f4a009d1ac/percheron-therapeutics-updates-on-avicursen-primate-toxicology-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/067c391486d9cdaa/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9bf53974951e557d/summit-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8bcdd4bef8e5398e/concept-medical-announces-successful-sirona-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/35c1ac0b7698401a/sarepta-files-duchenne-muscular-dystrophy-gene-therapy-with-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b3beb839c58f8c00/camurus-provides-regulatory-update-on-the-us-nda-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/405288fbd8d8d748/recursion-pharmaceuticals-inc-rxrx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1a3b307920de850b/nippon-shinyakus-dmd-drug-fails-confirmatory-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d063cc19f5520abc/clinical-trial-protocol-deviations-a-new-fda-draft-guidance-to-ring-in-the-new-year 2025-01-06T22:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/d1525cbcf21001d7/poly-adp-ribose-polymerase-parp-inhibitor-regimens-for-platinum-sensitive-ovarian-frontiers 2025-01-06T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/209827e7bc228fc5/with-phase-iii-success-pharmaessentia-to-seek-besremi-label-expansion 2025-01-06T22:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/c2eb7e034364a455/accelerated-approval-us-fda-explains-when-a-confirmatory-trial-is-underway 2025-01-06T22:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/555b0dd4c12b6e98/cytomx-therapeutics-announces-2025-strategic-pipeline-priorities-and-provides-corporate-update 2025-01-06T22:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/e783ace696939e7f/denali-therapeutics-als-drug-trial-falls-short-as-dnl343-misses-primary-endpoint 2025-01-06T21:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/5894c54dc263c2f2/updated-acelyrin-s-stock-drops-due-to-mixed-phase-2-data 2025-01-06T21:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/289079f68f898fcd/stimulating-fat-cells-with-gip-receptor-has-potential-to-treat-obesity 2025-01-06T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/8849f62d482b87cb/upamostat-combo-demonstrates-tolerability-in-metastatic-pancreatic-cancer 2025-01-06T21:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/0fd254258db98795/arcturus-therapeutics-announces-initiation-of-dosing-in-phase-2-multiple-ascending-morningstar 2025-01-06T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/366b8bdcc8b9b920/mrd-status-prior-to-allo-hsct-shows-strong-prognostic-value-in-aml-mds 2025-01-06T21:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/fd22125a0eea3a54/medtronic-s-harmony-tpvr-system-gains-ce-mark-approval-cardiovascular-business 2025-01-06T20:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/8f65fe76a721124e/sti-prevention-method-shows-promise-in-curbing-infections-in-groups-at-high-risk 2025-01-06T20:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/b93be88018dd3ebf/fda-grants-fast-track-designation-to-star-therapeutics-vga039-for-von-willebrand-disease 2025-01-06T19:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/f97af4f284f0303c/second-line-axi-cel-is-efficacious-safe-in-real-world-patients-with-r-r-lbcl-onclive 2025-01-06T19:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/282d61ca6f7c3605/study-confirms-ct-p42-therapeutic-equivalence-to-reference-aflibercept-in-dme 2025-01-06T19:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/f8312a653829f4b7/dr-levee-on-immune-related-aes-associated-with-icis-in-early-breast-cancer-onclive 2025-01-06T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/75c961cd9ba98d00/pharmaessentia-announces-positive-topline-phase-3-data-from-surpass-et-study-biospace 2025-01-06T19:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/877276a8e2c1e65d/fda-issues-draft-guidance-on-including-tissue-biopsies-in-clinical-trials-biospace 2025-01-06T19:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/af76739af1089cee/cms-issues-permanent-reimbursement-code-for-anktiva-urology-times 2025-01-06T19:00:31+00:00 hourly 0.9 https://trial.medpath.com/news/213f049d09eac327/viking-therapeutics-and-structure-therapeutics-seen-as-key-partners-in-weight-loss-market 2025-01-06T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/a7daf0be082b841c/abbott-india-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-ursodeoxycholic-acid-tablet 2025-01-06T18:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/6040a535cdd1e578/relativity-047-extended-analysis-of-overall-survival-with-nivolumab-relatlimab-vs 2025-01-06T18:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/43abcf1d22c19184/impact-of-non-abl1-mutations-on-outcomes-in-chronic-myeloid-leukemia 2025-01-06T18:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/74c37be23e6f1412/dose-escalation-completed-for-rise-therapeutics-r-3750-and-r-2487-clinical-trials 2025-01-06T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/73ae1710797b4129/dog-aging-project-receives-7-million-nih-grant-to-expand-clinical-trial-of-anti-aging-drug 2025-01-06T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/f721cdfc08793d0e/inmune-bio-s-treatment-for-epidermolysis-bullosa-awarded-fda-orphan-designation 2025-01-06T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/15c659963df8167f/crispr-repairs-limb-girdle-muscular-dystrophy-2b-mutation-and-phenotypes-in-patient 2025-01-06T16:44:10+00:00 hourly 0.9 https://trial.medpath.com/news/cca3951b28632599/insight-003-trial-of-eftilagimod-alpha-combo-in-nsclc-completes-enrollment 2025-01-06T16:38:35+00:00 hourly 0.9 https://trial.medpath.com/news/da5d6b2b84439ead/tarlatamab-earns-uk-approval-for-previously-treated-es-sclc-onclive 2025-01-06T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/news/0e23d9be278b7124/nanovibronix-completes-pilot-phase-of-us-trial-with-uroshield 2025-01-06T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/ccdbba2821a91048/study-finds-chemotherapy-antidote-could-improve-recovery-after-mass-general-brigham 2025-01-06T16:13:25+00:00 hourly 0.9 https://trial.medpath.com/news/a8c03602cf8e2e54/castle-biosciences-gains-new-york-state-approval-for-barrett-s-oesophagus-test 2025-01-06T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/fd116fefdd05b0a6/sean-m-healey-amg-center-announces-update-in-als-platform-trial-with-fosigotifator 2025-01-06T16:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/6bfc945b6019b793/veliparib-and-temozolomide-combo-does-not-significantly-extend-survival-for-patients-with-glioma 2025-01-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c99fc39b5e6e208e/10-clinical-trials-of-2024-hits-misses-and-some-in-between-citeline-news-insights 2025-01-06T15:42:34+00:00 hourly 0.9 https://trial.medpath.com/news/819a7a07c23a3b2d/adverse-events-of-hepatic-anti-fibrotic-agents-in-phase-3-and-above-clinical-trials-frontiers 2025-01-06T15:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/612b4282b7943263/serina-therapeutics-advances-parkinson-s-treatment-with-ser-252-clinical-trials-set-for-2025 2025-01-06T15:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/05417a2123c1d2de/woman-cancer-free-after-uk-s-first-liver-transplant-for-advanced-bowel-cancer 2025-01-06T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8b42146318ae368/atopic-dermatitis-clinical-trials-2024-a-comprehensive-overview 2025-01-06T15:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/a4d0940acb1ef910/imetelstat-plus-ruxolitinib-demonstrates-tolerable-safety-profile-in-myelofibrosis-onclive 2025-01-06T15:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/2d7d10fb66f62cb6/caribou-biosciences-price-target-increased-by-brookline 2025-01-06T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/fd6c3477fddc523c/eli-lilly-seeks-to-join-lawsuit-on-compounded-drugs-stat-news 2025-01-06T14:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/82db963429677c96/esophageal-cancer-market-report-2034-epidemiology-pipeline-therapies-and-latest-approvals 2025-01-06T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/62c23c5fa81780db/amylyx-pharmaceuticals-appoints-dan-monahan-as-chief-commercial-officer-morningstar 2025-01-06T14:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/434b0e5fa619a529/neurosense-regains-compliance-with-nasdaq-s-minimum-equity-requirement-stock-titan 2025-01-06T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/4673ac150e7686fe/anito-cel-demonstrates-safety-and-early-efficacy-in-r-r-multiple-myeloma-onclive 2025-01-06T14:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/1f7efef92e922ef1/investigators-hope-for-potential-breakthrough-in-dual-cellular-therapy-approach-for 2025-01-06T13:58:13+00:00 hourly 0.9 https://trial.medpath.com/news/e2da152df416bf03/quoin-s-netherton-syndrome-treatment-shows-dramatic-83-symptom-reduction-in-clinical-trial 2025-01-06T13:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/a9c04f9102f597cf/organovo-announces-appointment-of-norman-staskey-as-chief-financial-officer 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/17e0496779bbee53/nocira-r-grows-patent-portfolio-for-personalized-adaptive-migraine-treatments 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/dcc29efcf44b4be0/unity-biotech-appoints-syfovre-developer-dr-grossi-as-cmo-ahead-of-key-dme-trial 2025-01-06T13:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/062c5d5ad906cabf/spectral-medical-provides-december-tigris-trial-update-financial-post 2025-01-06T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/06330fe0641cd93d/casi-pharmaceuticals-launches-pivotal-phase-1-2-trial-for-novel-itp-treatment-cid-103 2025-01-06T13:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/d2fc7c15d6eee1ca/fda-reviews-cutx-101-for-menkes-disease-treatment-investing-com 2025-01-06T13:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/ff16e425d1ea2619/stroke-care-device-maker-wellumio-expands-u-s-footprint-massdevice 2025-01-06T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/e24a945256bcf787/iparomlimab-tuvonralimab-plus-chemo-bevacizumab-yields-responses-in-recurrent-onclive 2025-01-06T13:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/efa0d2437cc531fc/extended-paxlovid-may-help-some-people-with-long-covid-uc-san-francisco 2025-01-06T13:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/12deb24834ae6b89/lineage-cell-therapeutics-updates-shareholders-on-progress-and-2025-outlook 2025-01-06T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/e1d42678685b0f64/unity-biotechnology-prepares-for-key-data-readouts-in-2025-for-ubx1325-in-diabetic 2025-01-06T12:46:31+00:00 hourly 0.9 https://trial.medpath.com/news/21059a89c25202d7/vyne-therapeutics-completes-phase-2b-trial-enrollment-for-novel-vitiligo-treatment-vyn201 2025-01-06T12:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/179f612b6b2d8c50/xortx-launches-xrx-026-program-for-allopurinol-intolerant-gout-patients-targets-fda-approval 2025-01-06T12:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/f406aa76d2460353/cytomed-therapeutics-signs-business-research-globenewswire 2025-01-06T12:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/26b805d89af3cbae/essex-bio-technology-completes-phase-3-study-for-wet-amd-treatment-markets-insider 2025-01-06T11:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/f801f217337b1a6f/uk-conditionally-approves-amgen-s-drug-for-aggressive-lung-cancer-in-pretreated-patients 2025-01-06T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/887fc3822faf1cb2/nasdaq-grants-revelation-biosciences-inc-continued-listing-stock-titan 2025-01-06T11:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/22646eb50f303987/glecirasib-in-kras-g12c-mutated-nonsmall-cell-lung-cancer-a-phase-2b-trial-nature 2025-01-06T11:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/c3db175b36d9f80b/selumetinib-in-adults-with-nf1-and-inoperable-plexiform-neurofibroma-a-phase-2-trial 2025-01-06T11:13:44+00:00 hourly 0.9 https://trial.medpath.com/news/b76582ac4d464e2b/prediction-of-checkpoint-inhibitor-immunotherapy-efficacy-for-cancer-using-routine-blood 2025-01-06T11:13:42+00:00 hourly 0.9 https://trial.medpath.com/news/e8f69b5bb76ed97a/hope-therapeutics-acquires-dura-medical-to-expand-interventional-psychiatry-network-in-florida 2025-01-06T11:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/1f061756c6d2ee54/study-finds-no-clinical-advantage-of-budesonide-inhaler-over-fluticasone-in-copd 2025-01-06T11:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/4671e0f4ac1c25d3/european-medicines-agency-commences-review-of-donidalorsen-in-hereditary-angioedema 2025-01-06T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/efc2592b0ce35f39/open-label-randomised-clinical-trial-investigating-whether-robot-assisted-kidney 2025-01-06T10:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/c6515d5321145df1/defence-therapeutics-secures-key-patent-allowances-for-accum-r-multimer-technology-and-vaccine-platform 2025-01-06T10:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/ce35d2aa43d408c1/study-reveals-optimal-age-to-stop-colorectal-cancer-screening-based-on-individual-risk-factors 2025-01-06T09:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/46eed7d4f91f71de/the-biotech-scorecard-for-the-first-quarter-16-stock-moving-events-to-watch 2025-01-06T09:36:23+00:00 hourly 0.9 https://trial.medpath.com/news/babe735dfbe52bcc/do-glp-1-receptor-agonists-increase-the-risk-of-suicide-in-patients-news-medical 2025-01-06T09:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec26310ef59ed162/2025-cure-parkinson-s-research-highlights-from-the-last-year-and-insights-for-the-year-ahead 2025-01-06T09:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/3e295248c0f75b96/sidra-medicine-advances-innovation-and-expands-precision-medicine-efforts 2025-01-06T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/43bc18628ee6674d/oculis-announces-positive-ocs-05-phase-2-acuity-trial-in-acute-optic-neuritis-met-stock-titan 2025-01-06T09:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/f87b26bf746b6f9d/car-t-cell-therapy-shows-promise-for-transformed-indolent-non-hodgkin-lymphoma 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/faf2a9b22a756fa3/senti-bio-secures-additional-11-5-million-in-financing-to-advance-gene-circuit-based-therapies 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1aaac345c8e90546/denosumab-shows-superior-fracture-prevention-in-dialysis-patients-despite-cardiovascular-risks 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/209e124a92ed75fe/naya-biosciences-expands-oncology-pipeline-with-new-antibody 2025-01-06T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/e0ac31285118aec6/sagimet-biosciences-to-present-fasn-inhibitor-research-at-mash-tag-2025-conference 2025-01-06T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/30272dd1cff8112b/qpop-platform-shows-87-success-rate-in-personalizing-aml-treatment-selection 2025-01-06T08:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/2376ebc11031c558/nuclein-achieves-dual-fda-510-k-clearance-and-clia-waiver-for-dash-r-sars-cov-2-flu-a-b-test 2025-01-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/39479e50387a6036/adc-therapeutics-completes-enrollment-for-lotis-5-phase-3-trial-reinforcing-zynlonta-s-potential-in-dlbcl-treatment 2025-01-06T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c92155e70873fbc/orbis-medicines-raises-eur90m-series-a-to-advance-oral-macrocycle-drug-development 2025-01-06T07:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/1254989c6ce8335f/european-commission-ec-extends-the-approval-of-evkeeza-r-globenewswire 2025-01-06T07:10:42+00:00 hourly 0.9 https://trial.medpath.com/news/d1a45ba4bf963bad/large-meta-analysis-reveals-link-between-high-fluoride-exposure-and-reduced-iq-in-children 2025-01-06T06:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/d2dc37579da20029/intranasal-insulin-shows-promise-in-combating-diabetes-related-cognitive-decline 2025-01-06T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/dcaefee07ca138ce/nmd-pharma-announces-fda-orphan-drug-designation-granted-to-globenewswire 2025-01-06T06:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/5cac462121bd1d9c/natural-weight-loss-drug-as-effective-as-ozempic-and-without-side-effects-academics-claim 2025-01-06T05:58:31+00:00 hourly 0.9 https://trial.medpath.com/news/efc5743c478613fc/opinion-the-cocktail-recipe-that-will-cure-alzheimer-s-biospace 2025-01-06T05:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/b9da3b11293de07f/evidence-mounts-for-benefit-of-glp-1s-against-heart-disease-biospace 2025-01-06T05:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/4189d70b1f306dbd/a-randomized-double-blind-placebo-controlled-trial-protocol-for-a-fu-jpr-dove-medical-press 2025-01-06T05:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/7a12a4fa6dff92c0/brainstorm-advances-with-phase-3b-trial-of-nurown-r-in-als-and-secures-new-patent-for-exosome-technology 2025-01-06T05:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/72ef8878afcd5d76/adjunctive-pcsk9-inhibitor-evolocumab-in-the-prevention-of-early-neurological 2025-01-06T04:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/359a5a013a07577a/mobile-nurse-visits-show-promise-in-clinical-trials-industry-survey-reveals-91-retention-benefit 2025-01-06T03:44:23+00:00 hourly 0.9 https://trial.medpath.com/news/2c607e44abf26f12/observational-pilot-study-of-switching-from-entecavir-to-tenofovir-alafenamide-in-patients-with 2025-01-06T03:30:06+00:00 hourly 0.9 https://trial.medpath.com/news/d81286061ecf8452/australia-launches-a-35-7m-grant-initiative-to-enhance-clinical-trial-infrastructure 2025-01-06T02:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/ecf1fcd6185307a8/effect-of-intravenous-urokinase-vs-best-medicine-treatment-on-functional-outcome-for 2025-01-06T01:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/e20fee04dee89eb7/health-check-percheron-board-addresses-shareholders-after-failed-phase-2b-trial 2025-01-06T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/b3ada578c6968918/new-nmosd-treatment-gains-pbs-recommendation-ms-australia 2025-01-06T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/e32f333b4aa667ce/strategic-r-d-resource-allocation-the-hidden-risks-of-over-investing-in-single-drug-development 2025-01-06T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/94bdb349d2bebec7/guess-which-all-ords-asx-healthcare-stock-just-surged-11-on-fda-news-motley-fool 2025-01-06T00:42:54+00:00 hourly 0.9 https://trial.medpath.com/news/9c3d6f8f86ad7c01/china-s-national-medical-products-administration-nmpa-approves-vyloy-markets-data 2025-01-06T00:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/a8d3f485e56b8a2f/tcl1a-protein-identified-as-predictor-of-blinatumomab-response-in-relapsed-b-all 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/444f4697825487ef/brentuximab-vedotin-shows-strong-real-world-efficacy-in-chinese-alcl-patients-multi-center-study-finds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5b5d171a8780d1c5/technoderma-medicines-reports-positive-phase-2a-trial-results-for-tdm-180935-in-atopic-dermatitis 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f55bebdb6bbc3a25/glucarpidase-for-treatment-of-high-dose-methotrexate 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b3a1e5c3a3411fd5/sage-and-biogen-s-zuranolone-shows-promise-in-phase-3-trials-but-faces-commercial-uncertainty 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/03044c817e3d8de5/fda-approves-test-to-identify-patients-at-risk-of-opioid-use-disorder 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b62ff44e9729d54/citius-shares-jump-after-reporting-positive-results-from-early-study-of 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/daf082637bbb0173/insulin-beats-oral-alternatives-for-gestational-diabetes-outcome 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5fcc121e278d3dd7/mepolizumab-in-chronic-rhinosinusitis-with-nasal-polyps-real-life-data 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/123c17595a4aa63a/gene-therapy-trial-for-geographic-atrophy-shows-limited-efficacy-despite-sustained-factor-i-expression 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8a4f627f7ab2b8f/oculis-price-target-raised-to-31-from-23-at-bofa 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d1bf01810680b9bb/advancements-in-retina-and-vitreous-treatments-highlighted-in-recent-studies-and-collaborations 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9e8b812387755fc/fda-issues-much-anticipated-guidance-on-pulse-oximeters 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/14d1edd5120bf39f/cytomed-a-singapore-biotech-revolutionizes-cancer-treatment-using-donor-immune-cells 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/79cd758faa13addf/bms-announces-positive-reblozyl-phase-3-results-for-mds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/79288e54d5f4cdff/bayer-advances-asundexian-to-phase-3-trials-despite-mixed-phase-2-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4f113b77a34b780e/stoke-therapeutics-to-host-webcast-to-discuss-successful 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b3a784687e0f71d/moderna-receives-fda-approval-for-rsv-vaccine-mresvia 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d636545fc5bf0e53/gilead-s-trodelvy-fails-in-bladder-cancer-trial 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b0aa2430fe5ef32/fda-approves-abrysvo-for-adults-18-59-at-increased-risk-for-rsv 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d5a454fd873b0fc8/promising-clinical-results-and-market-potential-drive-buy-rating-for-oculis-holding 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7793b1515edae719/fda-panel-approves-sage-s-novel-antidepressant-for-postnatal-depression-rejects-alkermes-treatment 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fcd8d88b7b0f0ef4/non-opioid-pain-relievers-outperform-opioids-after-dental-surgery 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a631a781b217aa60/dana-farber-launches-gene-therapeutics-center 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c77508e81cc32476/i-mab-announces-portfolio-prioritization-of-givastomig-cldn18-2-x-4 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/caea05e60c85c872/new-insights-on-hypertension-treatment-combination-pills-and-medication-timing 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e4883d15195ce644/tanvex-biopharma-faces-second-fda-crl-for-herceptin-biosimilar 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec2379eb222d46bc/fecal-transplants-show-promise-in-alleviating-gi-symptoms-in-type-1-diabetes-patients 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/594f6803f0e8d634/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ca798afe3131a469/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4cd87e3f4ca0b31b/theralase-technologies-advances-bladder-cancer-treatment-with-promising-phase-ii-trial-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9c76dee3723d098/percheron-therapeutics-regroups-after-clinical-trial-results-vows-to-continue-to-conserve 2025-01-05T23:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/340ba4389d6c0d85/ebr-systems-awaits-fda-inspection-for-wireless-cardiac-device-tipranks-com 2025-01-05T23:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/9ad3cd416b1e10a6/rct-2100-by-recode-therapeutics-for-cystic-fibrosis-likelihood-of-approval 2025-01-05T21:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/cefa0b11beb09918/los-angles-shigellosis-outbreak-caused-by-mutation-vax-before-travel 2025-01-05T19:45:52+00:00 hourly 0.9 https://trial.medpath.com/news/c0d74797a42b2fdd/dopamine-s-surprising-breakthrough-in-alzheimer-s-treatment-rolling-out 2025-01-05T19:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/d92fa27653fbf32e/cdsco-panel-approves-novartis-protocol-amendment-proposal-for-tin816-study-in-sepsis 2025-01-05T19:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/b58cc16d1e873b70/lanarkshire-dad-with-mnd-backs-ps350k-campaign-to-help-fund-miracle-drug-trial-glasgow-live 2025-01-05T17:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/be2ed39138165483/fda-action-update-december-2025-approval-designations-and-clinical-hold 2025-01-05T17:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/6759e5f202a42d6b/groundbreaking-mrna-vaccine-revolutionizes-pancreatic-cancer-treatment 2025-01-05T16:42:31+00:00 hourly 0.9 https://trial.medpath.com/news/a09977a58c40ecd5/marine-fungi-a-promising-source-of-novel-antibiotics-in-the-fight-against-drug-resistance 2025-01-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/19183f0fd1da782b/car-t-warning-for-secondary-malignancies-warranted-or-not-medpage-today 2025-01-05T15:49:33+00:00 hourly 0.9 https://trial.medpath.com/news/9ee8672a76027665/new-toolkit-shows-promise-in-improving-sickle-cell-trait-documentation-during-infancy 2025-01-05T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d309831f545ba1b/lung-protective-ventilation-guided-by-driving-pressure-improves-pulmonary-outcomes-in-nature 2025-01-05T11:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/2118c62c9a5e222e/abbvie-s-telisotuzumab-adizutecan-shows-promise-across-multiple-solid-tumors 2025-01-05T10:00:57+00:00 hourly 0.9 https://trial.medpath.com/news/5d49b55697153776/taiho-pharmaceutical-advances-astx-295-novel-mdm2-inhibitor-in-glioblastoma-and-multiple-cancer-types 2025-01-05T09:37:55+00:00 hourly 0.9 https://trial.medpath.com/news/0334b409a16ed4dd/novel-car-t-cell-therapy-scar-02-shows-promise-for-multiple-autoimmune-conditions 2025-01-05T09:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/f92c318eeb79ca41/genentech-advances-ro-7759065-development-for-metastatic-solid-tumors 2025-01-05T09:37:21+00:00 hourly 0.9 https://trial.medpath.com/news/772a6ea3a3a1dbb1/abbvie-advances-novel-nlrx1-targeting-drug-amelenodor-for-inflammatory-bowel-disease-treatment 2025-01-05T09:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/0b871c2ab2dcccd0/synthekine-advances-novel-il-2-based-combination-therapy-for-refractory-cll-treatment 2025-01-05T09:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/be3d8b892ea867b9/j-j-advances-novel-liposomal-vaccine-jnj-2056-for-alzheimer-s-and-tauopathies 2025-01-05T09:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/463e0f2e68f4445e/could-lymph-node-surgery-be-the-answer-for-treating-alzheimer-s-disease 2025-01-05T09:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/95971c77112376ea/dragonboat-biopharmaceutical-advances-cetuximab-biosimilar-development-for-multiple-cancer-indications 2025-01-05T08:56:22+00:00 hourly 0.9 https://trial.medpath.com/news/60d75cf457ff3cc9/high-fiber-diet-shows-promise-in-obesity-management-opening-new-paths-for-pharmaceutical-development 2025-01-05T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/820776bab31c46ff/china-achieves-breakthrough-in-bci-clinical-trials-enabling-patient-to-convert-thoughts-into 2025-01-05T05:51:40+00:00 hourly 0.9 https://trial.medpath.com/news/1f65978cff0c1966/dual-biopsy-approach-enhances-precision-medicine-success-in-lung-cancer-treatment 2025-01-05T05:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/c3bb78fcdd9c9963/novel-metabolic-signatures-show-promise-for-earlier-pancreatic-cancer-detection-and-prognosis 2025-01-05T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1148e09a090d2501/expert-outlines-patient-specific-approach-for-io-combinations-in-unresectable-hcc-treatment 2025-01-05T03:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/9a4c840dc76762d7/the-holy-grail-of-heart-health-a-valve-that-grows-inside-you-the-times 2025-01-05T01:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/47c27d3ae110d8af/ariad-speeding-ponatinib-to-market 2025-01-05T00:53:54+00:00 hourly 0.9 https://trial.medpath.com/news/f8245675cadb32c3/uk-partners-with-biontech-on-clinical-trials-of-mrna-cancer-therapies 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/59dae942c011dee9/immupharma-lon-imm-stock-price-down-5-6 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6d494246407a159a/pfizer-and-lilly-s-non-opioid-pain-drug-tanezumab-shows-promise-in-phase-3-trial 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/72c2095c882a5b3b/first-chikungunya-vaccine-approved-by-fda 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b26803daa78afdf7/breakthroughs-in-clinical-trials-a-week-of-promising-developments 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8b74cf9e2d2c1fc0/fda-approves-roche-s-her2-breast-cancer-diagnostic 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/af24024b458c5ee6/sava-lawsuit-alert-levi-korsinsky-notifies-cassava-sciences-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e227710de41bdb99/kadmon-prepares-fda-filing-for-gvhd-drug-belumosudil-following-phase-3-success 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7de93ecd6056ee63/roche-partners-with-dicerna-for-hepatitis-b-gene-silencing-drug 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/171ffea89f92a904/who-s-thinking-healthy-programme-shows-promise-in-treating-perinatal-depression-in-chinese-hospitals 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/70db689c22c0f82f/paxlovid-reduces-hospitalization-and-death-risks-in-covid-19-patients-with-kidney-disease 2025-01-04T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/3b01077d49fe3d71/bms-986253-plus-nivolumab-ipilimumab-fails-to-boost-responses-in-advanced-melanoma 2025-01-04T17:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/cd2878c1b2df70ed/expanding-the-clinical-care-of-friedreich-ataxia-through-omaveloxlone-and-skyclarys 2025-01-04T16:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/c7459ebd15dd1cb9/efgartigimod-leads-to-sustained-myasthenia-gravis-improvement 2025-01-04T13:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/e52f41396abcfdf6/etanercept-and-infliximab-biosimilars-show-no-increased-infection-risk-comparable-safety 2025-01-04T12:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/f8b1fb3a174b93ea/new-hope-for-fibrolamellar-carcinoma-summit-trial-findings-targeted-oncology 2025-01-04T12:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/ce133adcbca44635/uw-madison-pioneers-ketamine-study-for-teens-with-ptsd 2025-01-04T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/f24b6c076234b7b1/merck-is-a-new-year-outlier-with-its-diabetes-drug-stat-news 2025-01-04T10:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/30b263f815b005d0/implementation-of-a-goal-directed-care-bundle-for-intracerebral-hemorrhage-plos 2025-01-04T09:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/510387d8e1dcc2a7/kaiser-permanente-pharmacist-outlines-key-challenges-in-value-based-care-implementation 2025-01-04T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf4ab760cf826d4e/nyu-perlmutter-cancer-center-combines-ai-and-community-health-workers-to-transform-clinical-trial-access 2025-01-04T06:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc232ed844cf962a/1st-stem-cell-therapy-new-hiv-drug-approved-chinadaily-com-cn 2025-01-04T06:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/79ae022412fbac3c/gi-cancer-treatment-faces-immunotherapy-hurdles-expert-calls-for-better-patient-education 2025-01-04T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cb22838616e4ff6b/losartan-use-found-to-safely-ease-rdeb-symptoms-in-children-in-trial-epidermolysis-bullosa-news 2025-01-04T05:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/e57cd823425093ad/99mtc-tc-hynic-ipsma-shows-promise-in-prostate-cancer-imaging-urology-times 2025-01-04T04:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/6caab80667f1fcf0/ethical-dilemma-physicians-navigate-challenges-of-repurposed-drugs-in-cancer-care 2025-01-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b5aa01161a009da5/incentivising-safe-sex-a-randomised-trial-of-conditional-cash-transfers-for-hiv-and-sti-prevention-in-rural-tanzania 2025-01-04T03:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/d9a1328122c78510/pharmaessentia-corp-submits-phase-iii-clinical-trial-of-p1101-for-pre-fibrotic-early-pmf-or 2025-01-04T02:44:10+00:00 hourly 0.9 https://trial.medpath.com/news/a5f31f1cdefec9e9/conventional-imaging-may-understage-prostate-cancer-new-data-suggest-urology-times 2025-01-04T01:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/5230fc22fe9b444a/applied-dna-sciences-advances-in-dna-technology-and-clinical-trials 2025-01-04T00:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/67c14462282d48e1/the-pikaso-trial-a-new-hope-for-preventing-post-traumatic-osteoarthritis 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f11e010a35f81276/a-new-hope-for-treatment-resistant-depression-the-rise-of-psychedelic-treatments 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f11fdf69ddaf9b5/dengue-vaccines-and-developments-in-2025 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e60e5d8664a0534a/bayer-advances-lung-cancer-therapy-into-phase-3-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b42485018065050/ucb-collaborates-with-science-37-on-virtual-clinical-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/58b2253f95654734/benitec-biopharma-reports-positive-interim-clinical-data-for-bb-301-in-opmd-treatment-study 2025-01-03T23:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec1fd6d36d560546/sun-pharma-secures-cdsco-approval-for-novel-acid-blocker-fexuprazan-in-india 2025-01-03T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/973423d6eff4f0b0/current-treatment-protocols-for-ph-all-treatment-targeted-oncology 2025-01-03T22:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/736eb8c410c58abe/japan-s-mhlw-approves-takeda-s-hyqvia-subcutaneous-injection-to-treat 2025-01-03T21:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/5c7cfb36e373cddc/sweden-s-mendus-clears-regulatory-path-for-vididencel-registration-trial 2025-01-03T21:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/a298b304164e1077/phase-3-data-show-potential-of-new-oral-treatments-for-gonorrhea-healio 2025-01-03T21:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/00405756a7768aa5/lpoxy-therapeutics-inc-acquires-key-assets-from-xeno-biosciences-inc-to-advance-c 2025-01-03T21:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/6d9dbf9501be3975/coronary-sinus-reducer-an-overlooked-treatment-for-stable-angina 2025-01-03T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/558ef3526f5b577e/real-world-data-shows-improved-responses-for-pembrolizumab-chemo-in-tnbc 2025-01-03T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/2dd6e509a2b5d41d/ticking-time-bomb-jimmy-carter-s-lasting-impact-on-cancer-breast-cancer-cvd-link 2025-01-03T20:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/5e138f90b13b62ab/stem-cell-therapies-that-work-10-breakthrough-technologies-2025 2025-01-03T18:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/eba4dd0ed4ec1ed3/landmark-va-fda-collaboration-will-compare-blood-thinners-in-new-head-to-head-clinical-trial 2025-01-03T18:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/bf58e7783649a842/novel-therapies-and-combinations-lead-the-way-in-women-s-cancers-in-2024 2025-01-03T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/4de52221892de96b/fda-approves-new-drug-that-delays-onset-of-type-1-diabetes-weyi 2025-01-03T18:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/2a9dc9ab977b6536/qurient-receives-u-s-phase-1b-approval-for-new-immunotherapy-drug-targeting-chronic-graft 2025-01-03T17:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/022ed1b930c4e344/merck-advances-oncology-portfolio-with-new-licensing-agreements-and-clinical-trial-updates 2025-01-03T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/925fa052adc4e663/elevation-oncology-promising-cancer-therapies-earn-analyst-praise 2025-01-03T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/9a43d98708efc3dc/addition-of-nab-paclitaxel-to-gemcitabine-cisplatin-in-advanced-biliary-tract-cancers 2025-01-03T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/e271416145740671/enthusiasm-for-transplant-free-strategies-for-low-risk-relapsed-hodgkin-lymphoma 2025-01-03T16:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/9479ceb2523e9fe2/ai-model-can-predict-high-blood-pressure-and-related-complications-from-ecgs 2025-01-03T16:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/b730d5adeb05587c/mass-general-brigham-reports-results-from-trial-of-skin-cancer-prevention-therapy 2025-01-03T15:54:06+00:00 hourly 0.9 https://trial.medpath.com/news/182e2a5081ded5c5/ocugen-will-continue-second-phase-of-ocu410-armada-clinical-trial-modern-retina 2025-01-03T15:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/8945bb88d87bc194/wockhardt-eyes-near-double-digit-margins-next-year-cnbc-tv18 2025-01-03T15:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/04cc7232fbdff3cc/fda-approves-new-drug-for-advanced-parkinson-s-disease 2025-01-03T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/2226098091ec154e/speckles-within-cancerous-tumors-can-determine-best-treatments-kff-health-news 2025-01-03T14:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/370e1ddd3879fea7/treatment-approaches-for-favorable-risk-metastatic-clear-cell-rcc-expert-perspectives-on-io-and-tki-combinations 2025-01-03T14:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/b68da7a537a57a5f/chime-biologics-and-mabgeek-achieve-mg-k10-ppq-milestone-advancing-atopic-morningstar 2025-01-03T14:23:01+00:00 hourly 0.9 https://trial.medpath.com/news/8a8f37f1dc068c44/sky-is-the-limit-for-adc-possibilities-in-nsclc-targeted-oncology 2025-01-03T14:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/72017b2283dc6e14/kitamaat-toddler-saved-thanks-to-clinical-trials-at-b-c-children-s-vancouver-sun 2025-01-03T14:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/3877791e0f96617d/diacarta-reports-positive-clinical-trial-data-for-its-blood-based-test-to-triage-fit-pr-newswire 2025-01-03T13:57:59+00:00 hourly 0.9 https://trial.medpath.com/news/47a9af70f6f8ea5e/amgen-s-imdyllytra-approved-by-mhra-to-treat-small-cell-lung-cancer-in-adults-pmlive 2025-01-03T13:54:04+00:00 hourly 0.9 https://trial.medpath.com/news/d10b8391a6a2f868/emerging-biotechs-challenge-pharma-giants-in-glp-1ra-market 2025-01-03T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9ac73cca8d89d9e/one-surgeon-s-spirit-and-brilliance-lift-a-whole-community-onclive 2025-01-03T13:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/71310c51308c2963/large-scale-study-finds-no-significant-link-between-psoriasis-and-alzheimer-s-risk-but-notes-slight-increase-in-vascular-dementia 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/94262ed18039340e/nivolumab-plus-avd-emerges-as-new-standard-for-advanced-hodgkin-lymphoma-treatment 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/99d13c160a6b9229/ai-adoption-grows-in-oncology-practice-despite-validity-and-ethics-concerns-survey-reveals 2025-01-03T12:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/2708e365fa82f4f0/eosinophilic-esophagitis-treatment-market-2034-ema-pdma-fda-openpr-com 2025-01-03T12:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/a080a276c87b32d5/siga-s-gains-approval-in-japan-for-orthopoxvirus-treatment-therapy 2025-01-03T12:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/09d14e72260f018a/adjuvant-immunotherapy-in-high-risk-muscle-invasive-urothelial-cancer-urotoday 2025-01-03T12:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/90c427056943e14d/hepatology-month-in-review-december-2024-hcplive 2025-01-03T12:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/a9dab4ce8ea9706a/takeda-s-oral-tyk2-inhibitor-matches-biologic-efficacy-drug-discovery-and-development 2025-01-03T11:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/ea4a485d1349ea88/research-error-sparks-unwarranted-concerns-over-heavy-metal-content-in-prenatal-vitamins 2025-01-03T11:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/e066267c2f66e034/study-reveals-significant-vascular-dysfunction-in-multiple-sclerosis-patients 2025-01-03T11:15:09+00:00 hourly 0.9 https://trial.medpath.com/news/819b76b5b918b6f1/personalized-autologous-neoantigen-specific-t-cell-therapy-in-metastatic-melanoma-a-phase-1-trial 2025-01-03T11:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/d5641256b77cdfa8/study-reveals-slower-visual-processing-in-glaucoma-patients-motor-skills-remain-intact 2025-01-03T10:51:20+00:00 hourly 0.9 https://trial.medpath.com/news/68299e9d1c055512/global-hiv-aids-crisis-latest-statistics-show-40-million-living-with-hiv-as-prevention-and-treatment-options-expand 2025-01-03T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/b51400b98e30b870/cathworks-completes-enrolment-in-cad-treatment-system-trial 2025-01-03T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/06edf0a4e9ab9e0b/deeper-response-predicts-better-outcomes-in-high-risk-smoldering-myeloma-nature 2025-01-03T09:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/a83871b071ff0c57/belite-bio-awaits-phase-iii-dragon-trial-data-can-it-fuel-further-gains 2025-01-03T09:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/02eaeb743f7d1e5f/integrated-pharmacists-significantly-improve-ibd-treatment-outcomes-and-cost-savings 2025-01-03T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c40a4bb16ce84b1f/gsk-s-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic 2025-01-03T07:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/1a8091602aabafd2/u-s-surgeon-general-pushes-for-enhanced-cancer-warning-labels-on-alcohol-products 2025-01-03T07:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/447164e04e865511/cdsco-approves-wockhardt-s-drug-miqnaf-to-treat-cabp-in-adults-the-hindu 2025-01-03T06:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/42a6037d34e64be9/lexaria-bioscience-corp-to-file-ind-application-with-fda-for-phase-1b-hypertension-clinical-trial 2025-01-03T04:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/91bcded28dd2f3a3/eli-lilly-moves-to-join-lawsuit-over-glp-1-compounding-as-fda-deadline-approaches 2025-01-03T04:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/e28807ff65a19a55/sichuan-baili-tianheng-pharmaceutical-co-ltd-voluntarily-disclosed-the-inclusion-of-bl 2025-01-03T03:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/a46c38b3c4314231/complement-factor-h-targeting-antibody-gt103-in-refractory-non-small-cell-lung-cancer 2025-01-03T02:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/33eadaf52e7c168b/trump-s-health-nominees-raise-concerns-over-wellness-industry-influence-on-public-health-policy 2025-01-03T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/48b638d72f426224/intravenous-liposomal-irinotecan-in-metastatic-triple-negative-breast-cancer-after-2-prior 2025-01-03T01:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/6c70b1f61817b771/acelyrin-inc-to-host-virtual-investor-event-to-share-new-phase-2-data-and-morningstar 2025-01-03T01:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/fc673fb5e58f9390/orchestra-biomed-shares-get-shot-in-the-arm-on-solid-clinical-trial-data 2025-01-03T00:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/55b6fba5a7ca87fc/what-s-going-on-with-acelyrin-shares-friday 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/169a842f17306df0/new-generation-of-car-t-therapy-shows-promise-in-treating-cll 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7f13222d21dab40/novel-nasal-swab-test-successfully-distinguishes-between-asthma-subtypes-in-breakthrough-study 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7e375c9ceb9941ab/imugene-doses-first-australian-patient-in-phase-1b-azer-cel-clinical-trial-proactive-investors 2025-01-02T23:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/6e0366466aa30b4c/bipolar-androgen-therapy-rationale-candidate-patients-and-latest-evidence-for-mcrpc-patients 2025-01-02T23:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/3ef611d474be4071/phase-ib-initial-data-loncastuximab-tesirine-lpyl-plus-glofitamab-effective-safe-in-dlbcl 2025-01-02T23:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/818055d4409e6e2b/boosting-reliability-ema-backs-ai-tool-for-mash-trials-citeline-news-insights 2025-01-02T22:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/fbe6e1a268e36d31/gi-alliance-offers-clinical-trial-opportunities-in-the-dallas-fort-worth-area-locations 2025-01-02T21:53:46+00:00 hourly 0.9 https://trial.medpath.com/news/72ab97ea6c6d893d/alx-oncology-faces-mixed-outcomes-in-clinical-trials-and-executive-changes 2025-01-02T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae72591bc58a15de/pembrolizumab-plus-sbrt-fails-to-improve-survival-in-unresected-stage-i-ii-nsclc 2025-01-02T21:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/70ed7aad982810c9/very-low-dose-rituximab-for-cad-may-not-sustainably-kill-b-cells 2025-01-02T20:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/4b8a77dfcd3ebf5b/results-from-nicotinamide-trial-highlighted-uci-mind 2025-01-02T19:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/f476b59cff067386/top-10-liver-disease-stories-of-2024 2025-01-02T19:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/34ecc67120bbc58c/college-of-medicine-researcher-receives-grant-to-further-pediatric-oncology-research 2025-01-02T18:46:15+00:00 hourly 0.9 https://trial.medpath.com/news/48bed444d332cbbf/azd0486-shows-good-efficacy-in-relapsed-refractory-follicular-lymphoma 2025-01-02T18:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/1575deabdd13e35b/hanx-biopharmaceuticals-ltd-announces-first-patient-dosing-in-first-in-human-phase-1 2025-01-02T18:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/6e4a668a2988fe19/top-10-fabry-disease-news-stories-of-2024 2025-01-02T17:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/b936f783645b12af/poolbeg-startles-investors-with-plan-to-hook-up-with-hookipa-citeline-news-insights 2025-01-02T16:54:20+00:00 hourly 0.9 https://trial.medpath.com/news/fe6788ea6ce0224b/capricor-completes-bla-submission-to-the-fda-for 2025-01-02T16:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/feeaa30ebdd940f9/for-alzheimer-agitation-a-novel-oral-nmda-inhibitor-could-be-the-next-targeted-treatment 2025-01-02T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/7c5c209191eb0a09/jiangsu-recbio-technology-co-ltd-announces-completion-of-phase-iii-clinical-trial-of-the 2025-01-02T16:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/b13878da7e40ddb5/os-therapies-to-attend-the-43rd-annual-jp-morgan-healthcare-conference-stock-titan 2025-01-02T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/c38bcede8043b2f7/study-of-sacituzumab-govitecan-misses-os-end-point-in-pretreated-urothelial-carcinoma 2025-01-02T15:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/7597922cf456f147/how-retail-pharmacies-are-bringing-clinical-trials-to-the-community 2025-01-02T14:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/2bc78863dbb17480/hemostemix-is-up-listing-in-the-usa-to-generate-liquidity-stock-titan 2025-01-02T14:41:12+00:00 hourly 0.9 https://trial.medpath.com/news/60e51e0d62601184/base-treatment-decisions-in-metastatic-breast-cancer-on-presence-of-esr1-mutations 2025-01-02T14:39:43+00:00 hourly 0.9 https://trial.medpath.com/news/2ea01591295bba31/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer-biospace 2025-01-02T14:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/8d1f62a02b139b81/capricor-files-landmark-fda-application-for-first-ever-dmd-cardiomyopathy-treatment 2025-01-02T14:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/8877a52328e67b67/benzodiazepine-agonist-treatment-for-patients-with-benzodiazepine-dependence-trials 2025-01-02T14:14:23+00:00 hourly 0.9 https://trial.medpath.com/news/f75a732953d1ed97/experimental-car-t-cell-therapy-shrinks-tumors-in-children-with-deadly-brain-cancer 2025-01-02T14:00:49+00:00 hourly 0.9 https://trial.medpath.com/news/a57fbf526b5ca5fd/silo-pharma-advances-ptsd-drug-spc-15-toward-clinical-trials-plans-2025-ind-filing 2025-01-02T13:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/d1b2348c08e564af/neumora-s-antidepressant-stumbles-in-first-phase-3-trial-readout-stat-news 2025-01-02T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/7b7e133c39fd8b57/cgtlive-s-2024-pillars-of-progress-top-news-in-lysosomal-disorders 2025-01-02T13:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/b4e7aa766eb23018/new-south-wales-to-introduce-year-long-pill-testing-trial-at-music-festivals-mixmag 2025-01-02T13:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/7a915575bf581722/phone-app-may-help-treat-opioid-use-disorder-data-suggests 2025-01-02T12:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/a30bdaa73aaecf89/nervgen-completes-enrollment-in-chronic-cohort-of-its-phase-1b-2a-clinical-trial-of-nvg 2025-01-02T12:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/ec4402f0b66a4606/fda-and-ema-feedback-endorses-vididencel-registration-trial-preparations-firstword-pharma 2025-01-02T12:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/84ac47691f5ff626/iit-guwahati-develops-precision-drug-hydrogel-for-cancer-treatment-with-fewer-side-effects 2025-01-02T12:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/0f3e6632da5604f2/sangamo-s-stock-plummets-as-pfizer-axes-hemophilia-gene-therapy-pact-biospace 2025-01-02T12:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/ab92f7e1bbb077a8/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2025 2025-01-02T12:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/3e1bf7fc8a61fd35/high-rate-of-asymptomatic-pulmonary-involvement-found-in-early-ra-and-psa-patients 2025-01-02T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c7a254743a72576/priority-health-expands-midwest-presence-with-acquisition-of-physicians-health-plan-of-northern-indiana 2025-01-02T11:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/0601d3c30963f103/new-framework-proposed-to-improve-hidradenitis-suppurativa-diagnosis-and-treatment-alignment 2025-01-02T11:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/10c0ebcb570b4878/empagliflozin-in-nondiabetic-individuals-with-calcium-and-uric-acid-kidney-stones-nature 2025-01-02T11:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/54d66051f198559d/neurologylive-r-year-in-review-2024-most-listened-podcast-episodes 2025-01-02T11:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/b311b1e994789c4f/gastroenterology-month-in-review-december-2024-hcplive 2025-01-02T11:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/463cdbc76d2a752a/real-world-insights-of-keynote-522-regimen-adoption-for-treating-triple-negative-breast-cancer 2025-01-02T10:57:31+00:00 hourly 0.9 https://trial.medpath.com/news/b3359d924f998980/psilocybin-shows-potential-for-treating-mental-health-disorders-in-people-with-cancer-and-addiction 2025-01-02T10:46:34+00:00 hourly 0.9 https://trial.medpath.com/news/33a573c6f584d4b5/mural-oncology-set-for-key-data-readouts-in-2025-for-nemvaleukin-alfa-in-ovarian 2025-01-02T10:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/836892c02d905df4/olanzapine-samidorphan-effects-on-weight-gain-an-individual-patient-data-meta-analysis 2025-01-02T10:16:13+00:00 hourly 0.9 https://trial.medpath.com/news/e3f6a918e827e835/global-trial-finding-a-cure-for-rare-childhood-cancer-opens-university-of-birmingham 2025-01-02T09:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/9ed265c67733a846/gyre-therapeutics-on-track-for-key-data-readouts-and-product-launches-in-2025 2025-01-02T09:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/94bd560d2fab4e90/innovent-and-roche-collaborate-on-promising-lung-cancer-therapy 2025-01-02T09:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/b9c006458ade7848/cspc-pharmaceutical-gains-breakthrough-status-for-cancer-therapy-tipranks-com 2025-01-02T09:18:31+00:00 hourly 0.9 https://trial.medpath.com/news/6f3adebf38191a18/patient-enrollment-concluded-early-in-pegasus-phase-3-pemphigus-trial-for-rilzabrutinib 2025-01-02T08:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/2fca7144bef47791/study-reveals-higher-mortality-and-complication-rates-for-esophagectomy-at-private-equity-owned-hospitals 2025-01-02T08:41:03+00:00 hourly 0.9 https://trial.medpath.com/news/12f62bc28feb6ae9/redefining-value-metrics-in-cancer-care-swedish-cancer-institute-director-calls-for-reform 2025-01-02T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/b301f83530c09cfe/colorado-launches-psilocybin-therapy-program-amid-regulatory-debates-and-veterans-advocacy 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/93661f166e69915f/travel-burden-analysis-reveals-higher-costs-for-epcoritamab-treatment-in-lymphoma-patients 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c83d26011622561/novartis-faces-whistleblower-lawsuit-over-alleged-ms-drug-kickback-scheme 2025-01-02T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/0db78f726c9f27cd/pioneer-in-pediatric-leukemia-treatment-transforms-global-outcomes-through-four-decades-at-st-jude 2025-01-02T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7952a5122c47a355/zhaoke-ophthalmology-reports-positive-trial-results-for-tab014-markets-insider 2025-01-02T03:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/7cdeb2583079ee78/pfizer-abandons-hemophilia-a-gene-therapy-program-returns-rights-to-sangamo 2025-01-02T03:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/57141e553b090fdb/biotech-stocks-facing-fda-decision-in-january-2025-rttnews 2025-01-02T02:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/a3345e05c6fdff61/critical-treatment-gap-persists-for-t2-low-asthma-despite-therapeutic-advances 2025-01-02T02:54:54+00:00 hourly 0.9 https://trial.medpath.com/news/fe09382793232ab6/cdsco-brings-clinical-trial-site-addition-and-change-of-pi-applications-to-online-mode 2025-01-02T02:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/aaeb0df0d1f8ce0b/hk-inno-n-speeds-up-developing-homegrown-obesity-drug-pharma-article-kbr 2025-01-02T02:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/1f8d792e10bde112/china-emerges-as-global-leader-in-rare-disease-clinical-trials-since-2020 2025-01-02T02:39:20+00:00 hourly 0.9 https://trial.medpath.com/news/cc67e75aadf933f7/korea-approves-rare-pediatric-chondrodysplasia-drug-voxzogo-policy-article-kbr 2025-01-02T02:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/70b9ed1c89cadbad/ai-revolutionizes-atopic-dermatitis-diagnosis-and-monitoring-with-advanced-technology-solutions 2025-01-02T02:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/59eb0cb85e65e70e/nhs-england-achieves-record-breaking-58-7-early-cancer-detection-rate-despite-treatment-access-challenges 2025-01-02T01:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/7d4598d2896706e0/will-tarlatamab-an-sclc-drug-developed-with-korea-s-help-be-introduced-here-this-year 2025-01-02T01:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/e8226c90abefaec3/patient-centric-strategies-reshape-oncology-trial-success-industry-experts-call-for-enhanced-engagement 2025-01-02T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/82b1fd699b720d36/chmp-rejects-neuraxpharm-and-apellis-drugs-companies-to-appeal 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/47dce06343e37c5d/fda-grants-orphan-drug-designation-to-micurx-s-mrx-5-for-ntm-infections 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/48b1f97796bf4c56/clinical-systems-news-events 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3c44d3a91757da6f/valo-health-halts-development-of-eye-disease-drug-seeks-partnership 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/69fea8507bf43860/tnf-inhibitors-reduce-fracture-risk-in-axial-spondyloarthritis-patients 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3f21f39f98e5af0b/immunization-most-read-stories-from-2024-drug-topics 2025-01-01T21:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/ea9e14212ca70b37/jefferies-starts-rhythm-pharmaceuticals-with-buy-on-obesity-potential-markets-insider 2025-01-01T18:46:13+00:00 hourly 0.9 https://trial.medpath.com/news/5cc19c7419934bde/merck-gets-u-k-approval-for-sotatercept-for-pah-msn 2025-01-01T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/1161f78e567a3ed9/sleep-quality-similar-between-youth-with-sickle-cell-disease-and-healthy-controls-but-quality-of-life-differs 2025-01-01T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/af0b26ccddef30fd/tempest-announces-agreement-with-roche-to-support-advancement-of-amezalpat 2025-01-01T16:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/83254b7e86ce196f/pipeline-watch-thirteen-approvals-and-eight-phase-iii-readouts 2025-01-01T15:40:56+00:00 hourly 0.9 https://trial.medpath.com/news/2f410a50903e481a/zongertinib-continues-to-improve-outcomes-in-advanced-her2-mutant-nsclc 2025-01-01T15:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/a53ab11916dd6b3b/study-protocol-for-covid-19-breakthrough-infections-and-vaccine-induced-immune-plos 2025-01-01T12:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/98573ba5e8f6556a/cinema-program-tackles-therapeutic-inertia-in-cardiometabolic-care-through-multi-faceted-approach 2025-01-01T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/630eea44b7fe6830/expert-outlines-personalized-monitoring-approach-for-myeloproliferative-neoplasm-management 2025-01-01T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/dbe91dc1003017ea/japan-approves-daiichi-sankyo-s-trop-2-adc-for-breast-cancer-bioworld 2025-01-01T10:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/fe99d8020ac1b123/news-in-brief-sotyktu-phase-iii-win-novo-s-alhemo-approval-axsome-agitation-data-pfizer 2025-01-01T09:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/fff54b8481468d61/importance-of-including-paediatric-experts-in-clinical-trials 2025-01-01T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/e27ff1fa3ede835f/a-novel-non-opioid-multimodal-analgesic-from-xgene-pharmaceutical-reduces-pain-and-a 2025-01-01T07:43:55+00:00 hourly 0.9 https://trial.medpath.com/news/9b583009af2cdbd6/iv-push-antibiotics-show-promise-for-faster-treatment-in-septic-shock-patients 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9cdaf5c65408bfc1/experts-debate-car-t-cell-therapy-options-comparing-yescarta-and-breyanzi-for-lymphoma-treatment 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3f6d8cd7cddf5904/scisparc-advances-autism-treatment-trial-cbd-based-sci-210-gets-key-israeli-approval 2025-01-01T06:54:06+00:00 hourly 0.9 https://trial.medpath.com/news/d0857bd18d6eb8c5/accc-fall-2024-innovations-in-clinical-trial-access-patient-care-and-treatment-authorization 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/695ccf312c6e5b3f/fda-faces-legal-challenge-over-tirzepatide-shortage-list-removal-agrees-to-reevaluation 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f0c065c694679872/penn-medicine-s-lynn-schuchter-three-decades-of-pioneering-melanoma-treatment-and-research 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/90f271770b05059f/liquid-biopsies-transform-lung-cancer-diagnostics-with-5-day-result-turnaround 2025-01-01T05:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/93b1b09d29ab525f/oncology-fellows-journal-seeks-input-to-shape-future-content-for-hematology-oncology-trainees 2025-01-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/511e0a269228b342/study-reveals-covid-19-causes-more-severe-kidney-function-decline-than-pneumonia 2025-01-01T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc8b7b735c2d63c7/cadrenal-therapeutics-provides-2024-year-end-company-update-reinforcing-clinical 2025-01-01T02:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/f11c5c71cda2d464/carsgen-announces-the-initiation-of-an-investigator-initiated-trial-for-an-allogeneic-cd19 2025-01-01T02:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/254b4d57ebccc377/cystic-fibrosis-sophie-pierce-ready-to-row-the-atlantic-bbc 2025-01-01T02:24:28+00:00 hourly 0.9 https://trial.medpath.com/news/e3310f1377e98071/looking-ahead-to-2025-dermatology-drug-approvals 2025-01-01T02:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/d9b07c96b3640a28/advancing-lung-cancer-treatment-with-bispecific-antibodies-a-review-of-amivantamab 2025-01-01T02:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/d0b7e944868dbf20/at-19-by-shanghai-yake-biotechnology-for-follicular-lymphoma-likelihood-of-approval 2025-01-01T00:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/f05d4207f51e075b/top-5-most-read-articles-on-myasthenia-gravis-in-2024 2025-01-01T00:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/15a6503fae975d29/bladder-tumor-focused-adaptive-radiotherapy-clinical-outcomes-and-feasibility 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd056597c5e7f917/scienture-secures-fda-orange-book-patent-listing-for-arblitm-losartan-potassium-oral-suspension 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f75311977c5293bf/alpha-cognition-s-oral-therapy-zunveyl-r-receives-fda-approval-to-treat 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/974770a79059adbf/beigene-announces-positive-phase-3-trial-results-for-tislelizumab-in-nasopharyngeal-cancer 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ad1a801a8e29fc0f/visugromab-plus-nivolumab-shows-promise-in-anti-pd-1-refractory-solid-tumors-by-targeting-gdf-15-pathway 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ad36a7a1ab42b7bc/systimmune-to-present-updated-izalontamab-brengitecan-data-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eecbe739ec010d2d/global-clinical-trials-review-on-friedreich-ataxia-for-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fc9993a9df7f6f44/a-new-horizon-in-alzheimers-disease-targeting-highly-neurotoxic-amyloid-b-oligomers-abos 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/39e4d3e06beadec6/scisparc-secures-japanese-patent-for-pain-relief-combo-by-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb790a846a247783/two-phase-iii-trials-target-advanced-breast-cancer-with-novel-therapeutic-approaches 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/27741fc03b45db3b/study-evaluates-new-treatment-for-non-healing-diabetic-foot-ulcers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4edcbbb68a22b765/regeneron-to-acquire-23andme-for-310-million-gaining-access-to-vast-genetic-database 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e728d064825c460c/dana-farber-cancer-institute-launches-phase-ii-trials-testing-immunotherapy-in-meningioma-and-melanoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/58798d208a96c5ef/itepekimab-met-the-primary-endpoint-in-one-of-two-copd-phase-3 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/960ed40ef9a97b08/roche-moves-antibiotic-against-superbug-into-phase-3-of-testing-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/add87bfe8a87e888/recce-pharmaceuticals-secures-strategic-patent-protection-in-china-for-antimicrobial-technology 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a8a2921df821ba63/pharmaceutical-asset-purchase-deals-show-sustained-growth-since-2019-report-reveals 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ee7e72ab55947de/fda-approves-gsk-s-nucala-for-copd-treatment-expanding-therapeutic-options 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a62b52773a31b0d1/phase-iii-trial-compares-proton-therapy-to-standard-radiation-for-leptomeningeal-metastasis-from-breast-and-lung-cancers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1c8e5b1e18017e21/fda-directs-covid-19-vaccine-manufacturers-to-update-formulations-for-fall-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8b0908e40e386cf9/abeona-therapeutics-sells-priority-review-voucher-as-nppa-sets-prices-for-84-new-drugs 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9072530660af03c6/compass-pathways-psilocybin-drug-meets-primary-endpoint-in-phase-3-trial-despite-market-disappointment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5532240f5d6aa246/gilead-sciences-announces-11-billion-investment-in-us-drug-manufacturing-expansion 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/09338971266d6c4c/study-on-inhaled-fexlamose-for-treating-moderate-to-severe-copd-in-adults 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/43fb1ad53bdb7ffe/merck-advances-v181-quadrivalent-dengue-vaccine-candidate-toward-june-2025-milestone 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5db0a2794a5d58d2/acadia-pharmaceuticals-announces-business-and-pipeline-updates-at-j-p-morgan-healthcare-conference 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e2f0db9d3748f35/novel-human-trial-finds-a-dopamine-continuous-intracerebroventricular 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7722959ea15b5211/phase-iii-trial-tests-yoga-as-non-pharmacological-treatment-for-chemotherapy-induced-peripheral-neuropathy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3940ea5a606b0538/schizophrenia-today-what-s-new-and-what-s-coming 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec24a3c44cdc3065/beigene-launches-global-phase-2-trial-of-zanubrutinib-for-relapsed-or-refractory-marginal-zone-lymphoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ba18a4c1bdfac3e/first-human-study-for-resistant-epilepsy-using-vagus-nerve-stimulation-device 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/097a6a3726a6c77f/novel-upar-targeting-imaging-agent-fg001-shows-promise-in-oral-and-oropharyngeal-cancer-surgery 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae0863182fcad79e/nivolumab-shows-promise-in-refractory-biliary-tract-cancer-with-22-response-rate-in-phase-ii-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1d760f7860d5f4cf/advancements-in-antibiotic-development-for-gram-negative-bacteria 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc62c8915127ee2b/beigene-s-brukinsa-receives-european-commission-approval-for-cll-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/05c2cfd494f47da9/a-phase-1-study-of-tyra-300-in-people-with-advanced 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/04f92fee74feb03c/beigene-s-brukinsa-approved-by-swissmedic-for-waldenstroms-macroglobulinemia-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b0a13959b9774ad/an-efficacy-and-safety-study-of-rpt193-in-adults-with-atopic 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d7408466b4e243e7/beigene-initiates-phase-i-clinical-trial-of-bgb-a317-in-china 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/807af1d61bf6c1e3/fda-approves-teal-health-s-at-home-hpv-test-expanding-cervical-cancer-screening-access 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/61033eb9b38592bb/fda-proposes-update-to-18-year-guidance-on-developing-biologics-biosimilars-and-vaccines 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a8c89fff063e2a0b/a-real-world-study-to-gain-clinical-insights-into-faricimab-fareal-study 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cf6e980b423ae6fc/ionis-reports-positive-phase-3-results-for-olezarsen-in-familial-chylomicronemia-syndrome 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7491f7a9c9b6d512/ema-issues-positive-opinion-on-poltreg-s-pediatric-investigation-plan-for-type-1-diabetes-treg-therapy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9fc307bd978f502c/actuate-therapeutics-reports-significant-survival-improvement-in-metastatic-pancreatic-cancer-phase-2-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6bfa7c6a2238e6ba/intensified-total-neoadjuvant-therapy-in-patients-with 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/87db6cfc432bc4a6/circassia-receives-fda-boost-for-copd-drugs-in-the-us 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a887321ff707c670/phase-1-study-of-tti-101-for-advanced-liver-cancer-patients 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9d5cdee8651ce886/aerpio-initiates-phase-2-trial-of-razuprotafib-for-covid-19-blood-vessel-damage 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d791af92c7c86d45/upc-rejects-boehringer-ingelheim-s-preliminary-injunction-against-zentiva-s-generic-nintedanib 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c11fef1cf9e32037/fda-deputy-commissioner-signals-potential-reforms-to-pdufa-program 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1916da010cb40a82/cytomx-therapeutics-initiates-combination-therapy-arm-in-phase-1-melanoma-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/58a2abfe96efe6a8/gsk-and-iteos-halt-development-of-tigit-immunotherapy-after-failed-lung-cancer-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f135db19b3dcf517/arch-biopartners-announces-financing-and-clinical-trial-progress 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c8244d2795c5483a/doxorubicin-plus-pembrolizumab-shows-promise-in-phase-2-trial-for-advanced-soft-tissue-sarcoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/df1a64a06e9fce9e/flot-combination-takes-the-lead-in-localized-ge-cancer-targeted-oncology 2024-12-31T22:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/58e6f8481f0227e9/omega-therapeutics-stock-hits-52-week-low-amid-financial-and-market-challenges 2024-12-31T20:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/a83e64ff9b2403c1/contagion-s-2024-top-stories-hepatitis-infections 2024-12-31T19:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/49abcdb7a7ced9f5/merck-wins-uk-approval-for-lung-disease-drug-acquired-in-11-billion-deal-westlaw-today 2024-12-31T19:52:37+00:00 weekly 0.7 https://trial.medpath.com/news/ec5f978f683147a7/veru-announces-the-sale-of-the-fc2-female-condom-r-internal-globenewswire 2024-12-31T19:32:06+00:00 weekly 0.7 https://trial.medpath.com/news/ca73b8c46e7e9224/cgtlive-s-2024-pillars-of-progress-top-news-in-hematology 2024-12-31T19:15:31+00:00 weekly 0.7 https://trial.medpath.com/news/24a2b2c95e5d182d/kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-type-c 2024-12-31T19:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/7d635864bc4bcb5a/explore-the-evolving-role-of-btk-inhibitors-in-cll-with-alexey-danilov-md-phd-onclive 2024-12-31T19:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/20a4d0eaa94b7818/immunocompromised-adults-show-weaker-response-to-rsv-vaccines-news-medical 2024-12-31T16:38:11+00:00 weekly 0.7 https://trial.medpath.com/news/9990788497fab5f6/leqselvi-approval-tops-healio-s-most-read-alopecia-news-in-2024 2024-12-31T15:55:10+00:00 weekly 0.7 https://trial.medpath.com/news/8512908b194674b5/kazia-therapeutics-shares-fall-after-fda-declines-accelerated-drug-approval 2024-12-31T15:29:30+00:00 weekly 0.7 https://trial.medpath.com/news/15961bb903e4a91a/brii-bio-announces-signing-of-asset-purchase-agreements-acquiring-brii-179-ip-rights 2024-12-31T15:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/71d3ce7c163c8f90/ec-approves-rybrevant-lazcluze-for-advanced-nsclc-treatment 2024-12-31T15:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/47822d2659eb8683/miracle-new-drug-trial-shrinks-cruel-aggressive-bladder-cancer-uk-news-daily-express 2024-12-31T15:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/c5e55b5fa124fc8b/corcept-therapeutics-submits-new-drug-application-for-relacorilant-to-treat-cushing-s-syndrome 2024-12-31T14:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/c719cb84893ad22e/diabetes-drug-appears-to-fight-lung-cancer-but-only-in-overweight-or-obese-patients 2024-12-31T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/c0dc24f3f8eee213/cocrystal-pharma-to-extend-phase-2a-influenza-challenge-study-with-oral-pb2-inhibitor-cc-42344 2024-12-31T13:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/aa29fb4d73da236c/advancing-precision-medicine-in-esophageal-squamous-cell-carcinoma-using-patient 2024-12-31T13:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/98593d97dc1d3282/daily-hong-kong-stock-market-news-briefing-december-31-tuesday-longport 2024-12-31T13:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/f8804b5b65702cc6/drug-repurposing-breakthroughs-established-medications-show-promise-in-cancer-lyme-disease-and-neurological-disorders 2024-12-31T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d4a1a49e2bdbec1e/managing-the-complex-balance-mpn-treatment-challenges-with-jak-inhibitors 2024-12-31T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a7c4063c8aecd260/safety-of-fezolinetant-for-treatment-of-moderate-to-severe-vasomotor-symptoms-due-to-menopause 2024-12-31T11:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/f83a651a55b04357/leerink-reiterates-outperform-rating-on-axsome-stock-amid-fda-uncertainty-for-auvelity 2024-12-31T10:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/33c0fa7b32f80ece/medicare-part-d-expands-mtm-services-to-include-hiv-aids-coverage-in-2025 2024-12-31T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7e8eef646640b100/medmira-reports-first-quarter-results-fy2025-biospace 2024-12-31T05:28:02+00:00 weekly 0.7 https://trial.medpath.com/news/4db88994203222a5/pioneer-in-lymphoma-research-dr-margaret-shipp-recognized-as-2024-giant-of-cancer-care 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0b7fbd79c2e5ff6d/nccn-updates-2024-major-guideline-changes-across-multiple-cancer-types 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/573094ff609adfe5/preliminary-study-of-utilizing-a-patient-derived-tumor-spheroid-model-to-augment-precision-nature 2024-12-31T04:35:36+00:00 weekly 0.7 https://trial.medpath.com/news/f996cd0e682a79f5/galera-therapeutics-completes-acquisition-of-nova-pharmaceuticals 2024-12-31T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bcb7a778109eadd8/pulmonology-in-2024-ai-integration-air-quality-crisis-and-advancing-lung-care-highlighted-in-annual-review 2024-12-31T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/42aad4d95a4bc39f/cutia-therapeutics-completes-promising-phase-ii-trials-markets-insider 2024-12-31T02:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/2cedb5fafdc8a790/yuhan-s-lung-cancer-drug-leclaza-secures-european-approval-in-combination-therapy 2024-12-31T02:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/847e12c2ba7441fd/the-beam-dr-annemarie-shepherd-on-proton-therapy-for-thymic-cancers-napt-celebrates 2024-12-31T01:43:18+00:00 weekly 0.7 https://trial.medpath.com/news/2286ab66b4fd0f35/continuous-glucose-monitoring-among-adults-with-type-2-diabetes-receiving-noninsulin-or-nature 2024-12-31T01:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/09751a6e2f06fb53/efficacy-and-safety-of-single-and-double-catheter-intrathecal-drug-delivery-systems-in-nature 2024-12-31T00:16:16+00:00 weekly 0.7 https://trial.medpath.com/news/8d6641332b0278ef/optima-trial-explores-predictive-test-for-chemotherapy-in-breast-cancer-treatment 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7ace63039e45e33c/merck-announces-findings-from-phase-2-keyvibe-002-trial-evaluating-an 2024-12-31T00:00:00+00:00 weekly 0.7